<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="163c129d-f4e2-484d-af96-c265c9a5e38c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title mediaType="text/x-hl7-title+xml">
      <content styleCode="bold">These highlights do not include all the information needed to use ENVARSUS XR<sup>®</sup> safely and effectively. See full prescribing information for ENVARSUS XR.
			<br/>
         <br/>ENVARSUS XR<sup>®</sup> (tacrolimus extended-release tablets), for oral use
			<br/>Initial U.S. Approval: 1994
		</content>
   </title>
   <effectiveTime value="20250226"/>
   <setId root="de2315b0-6344-43ac-9aea-3e3b68d828e7"/>
   <versionNumber value="16"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="028252150" root="1.3.6.1.4.1.519.1"/>
            <name>Veloxis Pharmaceuticals, Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="315974691"/>
                        <name>Rottendorf Pharma GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="928861723"/>
                        <name>Pharma Packaging Solutions, LLC dba Tjoapack, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="arp">
               <id root="6358ce94-c139-45b1-af00-8e4df6387962"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68992-3075" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Envarsus<suffix>XR</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Tacrolimus</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="0.75" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WM0HAQ4WNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TACROLIMUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y5L2157C4J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TACROLIMUS ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="30IQX730WE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 6000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LQA7B6G8JG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 188</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1P9D0Z171K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLATED HYDROXYTOLUENE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3075-3" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3075-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA206406" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150901"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>White to Off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">075;TCS</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68992-3010" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Envarsus<suffix>XR</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Tacrolimus</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WM0HAQ4WNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TACROLIMUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y5L2157C4J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TACROLIMUS ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="30IQX730WE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 6000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LQA7B6G8JG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 188</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1P9D0Z171K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLATED HYDROXYTOLUENE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3010-3" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3010-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA206406" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150901"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>White to Off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">1;TCS</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68992-3040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Envarsus<suffix>XR</suffix>
                        </name>
                        <formCode code="C42927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Tacrolimus</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="4" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WM0HAQ4WNM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TACROLIMUS</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y5L2157C4J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TACROLIMUS ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="30IQX730WE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 6000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LQA7B6G8JG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 188</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TARTARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1P9D0Z171K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLATED HYDROXYTOLUENE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="92RU3N3Y1O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIMETHICONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3040-3" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="68992-3040-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20150901"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA206406" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150901"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>White to Off-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">4;TCS</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="SBW">
               <id root="f01ccbbd-e883-4253-b7b5-b99b0c1bdbe5"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title mediaType="text/x-hl7-title+xml">WARNING: MALIGNANCIES AND SERIOUS INFECTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)].</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: MALIGNANCIES AND SERIOUS INFECTIONS<br/>
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="SRMC">
               <id root="ab80937b-80d2-4551-9684-14c329df8c7e"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="70%" align="left" valign="top"/>
                           <col width="30%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Cannabidiol Drug Interactions  (<linkHtml href="#S5.13">5.13</linkHtml>)</td>
                                 <td>7/2023</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S5.9">5.9</linkHtml>, <linkHtml href="#S5.10">5.10</linkHtml>, <linkHtml href="#S5.14">5.14</linkHtml>)</td>
                                 <td>4/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="655b2015-fc97-4d66-bb2c-b368f0451b10"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ENVARSUS XR is a calcineurin-inhibitor immunosuppressant indicated for:</paragraph>
                        <list>
                           <item>The prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants  (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>The prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="1629f7b4-da11-4568-afde-0f4146b56d9e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">
                        1.1 Prophylaxis of Organ Rejection in De Novo Kidney Transplant Patients
                     </title>
                     <text>
                        <paragraph>
                           ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="62067c10-cdb3-47bd-9058-381829362de0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">1.2 Prophylaxis of Organ Rejection in Stable Kidney Transplant Patients Converting from Immediate-Release Formulations</title>
                     <text>
                        <paragraph>ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="084d5e60-8879-4aae-8e69-353f1a3cd5bf"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Take once daily on empty stomach at the same time of the day, preferably in the morning. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>Avoid eating grapefruit or drinking grapefruit juice or alcohol. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>African-American patients may need to be titrated to higher dosages to achieve the target tacrolimus concentrations. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>Patients with severe hepatic impairment may require a lower starting dose. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>Frequent monitoring of trough concentrations is recommended. (<linkHtml href="#S2.5">2.5</linkHtml>)</item>
                        </list>
                        <table width="450" styleCode="Noautorules">
                           <tbody>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Toprule Botrule Lrule Rrule">Recommended ENVARSUS XR Initial Dosage</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Initial Oral Dosage</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Whole Blood Trough Concentration Range</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">De novo kidney transplantation</content> with antibody induction</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">0.14 mg/kg/day</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Month 1: 6-11 ng/mL &gt;Month 1: 4-11 ng/mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Conversion</content> from tacrolimus immediate-release formulations</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">80% of the pre-conversion dose of tacrolimus immediate-release</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Titrate to 4-11 ng/mL</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="06fe9896-894b-4e5c-be98-308169ac2d01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.1 Important Administration Instructions</title>
                     <text>
                        <list listType="unordered">
                           <item>ENVARSUS XR (tacrolimus extended-release tablets) is not interchangeable or substitutable with tacrolimus extended-release capsules, tacrolimus capsules, and tacrolimus for oral suspension. Under or overexposure to tacrolimus may result in graft rejection or other serious adverse reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content> ENVARSUS XR should not be used without the supervision of a physician with experience in immunosuppressive therapy.</item>
                           <item>ENVARSUS XR should be taken on an empty stomach consistently at the same time of the day, preferably in the
morning to ensure consistent and maximum possible drug exposure, at least 1 hour before a meal or at least 2 hours
after a meal <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </item>
                           <item>Advise patients to swallow ENVARSUS XR tablets whole with fluid (preferably water); patients must not chew,
divide, crush or dissovle the tablets.</item>
                           <item>If a dose is missed, instruct the patient to take it as soon as possible within 15 hours after missing the dose. Beyond
the 15-hour time frame, instruct the patient to wait until the usual scheduled time to take the next regular daily dose.
Instruct the patient not to double the next dose.</item>
                           <item>Patients should avoid eating grapefruit or drinking grapefruit juice or alcoholic beverage while taking ENVARSUS
XR <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="64266ddd-b5c8-4ac3-888e-0c3ad68ac5a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">
                        2.2 Dosing in De Novo Kidney Transplant Patients
                     </title>
                     <text>
                        <paragraph>
                           The recommended starting dose of ENVARSUS XR in de novo kidney transplant patients is 0.14 mg/kg/day. Titrate ENVARSUS XR dosage based on clinical assessments of rejection and tolerability and to achieve whole blood trough concentration ranges (see <content styleCode="bold">Table 1</content>).
                           
                        </paragraph>
                        <table width="750" styleCode="Noautorules" ID="table1">
                           <caption>Table 1. Recommended Tacrolimus Whole Blood Trough Concentration Ranges in Kidney Transplant Patients with Antibody Induction</caption>
                           <col width="20%"/>
                           <col width="40%"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold">Time Period Post Transplant</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Target Tacrolimus Whole Blood Trough Concentration Ranges</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> During Month 1</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6 to 11 ng/mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">&gt; Month 1</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4 to 11 ng/mL</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="78ab1221-03f9-4d25-8cc1-ea5b4ad6c67b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.3 Dosing for Conversion from Tacrolimus Immediate-Release Formulations</title>
                     <text>
                        <paragraph>To convert from a tacrolimus immediate-release product to ENVARSUS XR, administer ENVARSUS XR once daily at a
dose that is 80% of the total daily dose of the tacrolimus immediate-release product. Monitor tacrolimus whole blood
trough concentrations and titrate ENVARSUS XR dosage to achieve whole blood trough concentration ranges of 4 to 11
ng/mL.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="5eded2b7-1c84-40c8-964d-ba3aa7e03960"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.4 Dosing Adjustments in African-American Patients, Patients with Hepatic Impairment, Drug Interactions</title>
                     <text>
                        <paragraph>African-American patients, compared to Caucasian patients, may need to be titrated to higher ENVARSUS XR dosages to
attain comparable trough concentrations <content styleCode="italics">[see <linkHtml href="#S8.8">Use in Specific Populations (8.8)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Due to reduced clearance and prolonged half-life seen in patients with severe hepatic impairment (Child-Pugh ≥10) these
patients may require a lower starting dosage of ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Dose adjustments of ENVARSUS XR may be necessary when administered concomitantly with CYP3A inducers or
CYP3A inhibitors or cannabidiol <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9</linkHtml>, <linkHtml href="#S5.13">5.13)</linkHtml>, <linkHtml href="#S7.2">Drug Interactions (7.2</linkHtml>, <linkHtml href="#S7.3">7.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="cdb00d9d-0785-4410-94ac-cfd34bc59130"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">2.5 Therapeutic Drug Monitoring</title>
                     <text>
                        <paragraph>Measure tacrolimus whole blood trough concentrations at least two times on separate days during the first week after initiation of dosing and after any change in dosage, after a change in co-administration of CYP3A inducers and/or inhibitors or cannabidiol <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>],</content> or after a change in renal or hepatic function  <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6</linkHtml>, <linkHtml href="#S8.7">8.7)</linkHtml>]</content>. When interpreting measured concentrations, consider that the time to achieve tacrolimus steady state is approximately 7 days after initiating or changing the ENVARSUS XR dose.</paragraph>
                        <paragraph>Monitor tacrolimus whole blood trough concentrations using a validated assay [e.g., immunoassays or high-performance
liquid chromatography with tandem mass spectrometric detection (HPLC/MS/MS)]. The immunosuppressive activity of
tacrolimus is mainly due to the parent drug rather than to its metabolites. Immunoassays may react with metabolites as
well as the parent drug. Therefore, whole blood tacrolimus trough concentrations obtained with immunoassays may be
numerically higher than concentrations obtained with an assay using HPLC/MS/MS. Comparison of the whole blood
tacrolimus trough concentrations of patients to those described in the prescribing information and other published
literature must be made with knowledge of the assay method(s) employed.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="52183aab-2aea-4375-901d-7576b4603c5b"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Oval, white to off-white uncoated extended-release tablets debossed with “TCS” on one side:</paragraph>
                  <list listType="unordered">
                     <item>0.75 mg extended-release tablet: debossed with “0.75” on the other side.</item>
                     <item>1 mg extended-release tablet: debossed with “1” on the other side.</item>
                     <item>4 mg extended-release tablet: debossed with “4” on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended-release tablets: 0.75 mg, 1 mg, 4 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="74446540-e8a3-4bf3-85a8-e22448035b98"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ENVARSUS XR is contraindicated in patients with known hypersensitivity to tacrolimus or to any of the ingredients in ENVARSUS XR.</paragraph>
               </text>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to tacrolimus or any of the ingredients (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="ce50c6ce-dabd-4bce-a188-42c3518888a8"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Not Interchangeable with Other Tacrolimus Products: Instruct patients or caregivers to recognize appearance of ENVARSUS XR tablets. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>New Onset Diabetes after Transplant: Monitor blood glucose. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Nephrotoxicity (acute and/or chronic): May occur due to ENVARSUS XR, drug interactions or concomitant nephrotoxic drugs. Monitor renal function and tacrolimus blood concentrations; consider dosage reduction or temporary interruption of ENVARSUS. (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                           <item>Neurotoxicity: Including risk of posterior reversible encephalopathy syndrome (PRES); monitor for neurologic abnormalities; reduce dosage or discontinue ENVARSUS XR. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>Hyperkalemia: Risk may be increased with other agents associated with hyperkalemia; monitor serum potassium levels. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                           <item>Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (<linkHtml href="#S5.8">5.8</linkHtml>)</item>
                           <item>QT Prolongation: Consider obtaining electrocardiograms and monitoring electrolytes in patients at high risk. (<linkHtml href="#S5.10">5.10</linkHtml>)</item>
                           <item>Immunizations: Avoid live vaccines. (<linkHtml href="#S5.11">5.11</linkHtml>)</item>
                           <item>Pure Red Cell Aplasia: Consider discontinuation. (<linkHtml href="#S5.12">5.12</linkHtml>)</item>
                           <item>Thrombotic Microangiopathy, Including Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura: May occur, especially in patients with infections and certain concomitant medications. (<linkHtml href="#S5.14">5.14</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="448e0647-d4c1-4d37-b209-f135ba70bb3a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.1 Lymphoma and Other Malignancies</title>
                     <text>
                        <paragraph>Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies,
particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to
the use of any specific agent. Examine patients for skin changes and advise to avoid or limit exposure to sunlight and UV
light by wearing protective clothing and using a sunscreen with a high protection factor.</paragraph>
                        <paragraph>Post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV), has been reported in
immunosuppressed organ transplant patients. The risk of PTLD appears greatest in those individuals who are EBV
seronegative. Monitor EBV serology during treatment.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2eaa1d5a-9914-4705-a79c-d061bf131411"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.2 Serious Infections</title>
                     <text>
                        <paragraph>Immunosuppressants, including ENVARSUS XR, increase the risk of developing bacterial, viral, fungal, and protozoal
infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. Serious
viral infections reported include:</paragraph>
                        <list>
                           <item>Polyomavirus-associated nephropathy (especially due to BK virus infection),</item>
                           <item>JC virus-associated progressive multifocal leukoencephalopathy (PML), and</item>
                           <item>Cytomegalovirus (CMV) infections: CMV seronegative transplant patients who receive an organ from a CMV
seropositive donor are at highest risk of CMV viremia and CMV disease.</item>
                        </list>
                        <paragraph>Monitor for the development of infection and adjust the immunosuppressive regimen to balance the risk of rejection with the risk of infection <content styleCode="italics">[see <content styleCode="bold">
                                 <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                              </content>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="6e207400-eba4-4f53-b242-c00e23b98b0a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.3 Not Interchangeable with Other Tacrolimus Products-Medication Errors</title>
                     <text>
                        <paragraph>Medication errors, including substitution and dispensing errors, between tacrolimus capsules and tacrolimus extended-release
capsules were reported outside the U.S. This led to serious adverse reactions, including graft rejection, or other
adverse reactions due to under- or over-exposure to tacrolimus. ENVARSUS XR is not interchangeable or substitutable
with tacrolimus extended-release capsules, tacrolimus capsules or tacrolimus for oral suspension. Instruct patients and
caregivers to recognize the appearance of ENVARSUS XR tablet <content styleCode="italics">[see <linkHtml href="#S3">Dosage Forms and Strengths (3)</linkHtml>]</content> and to confirm with their healthcare provider if a different product is dispensed or if dosing instructions have changed.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="3b791f62-9a58-4c40-a469-0f86b6a82305"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.4 New Onset Diabetes after Transplant</title>
                     <text>
                        <paragraph>ENVARSUS XR caused new onset diabetes after transplant (NODAT) in kidney transplant patients, which may be reversible in some patients. African-American and Hispanic kidney transplant patients are at an increased risk. Monitor blood glucose concentrations and treat appropriately <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and </content>
                           <content styleCode="italics">
                              <linkHtml href="#S8.8">Use in Specific Populations (8.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="ff1a613b-4135-4411-a9c2-27ac348eff71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.5 Nephrotoxicity due to ENVARSUS XR and Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">ENVARSUS XR, like other calcineurin-inhibitors, can cause acute or chronic nephrotoxicity in transplant patients due to its vasoconstrictive effect on renal vasculature, toxic tubulopathy and tubular-interstitial effects. Acute renal impairment associated with tacrolimus toxicity can result in high serum creatinine, hyperkalemia, decreased secretion of urea and hyperuricemia, and is usually reversible. In patients with elevated serum creatinine and tacrolimus whole blood trough concentrations greater than the recommended range, consider dosage reduction or temporary interruption of tacrolimus administration.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The risk for nephrotoxicity may increase when ENVARSUS XR is concomitantly administered with CYP3A inhibitors (by increasing tacrolimus whole blood concentrations) or drugs associated with nephrotoxicity (e.g., aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors, protease inhibitors).  When tacrolimus is used concurrently with CYP3A inhibitors or other known nephrotoxic drugs, monitor renal function and tacrolimus blood concentrations, and adjust dose of both tacrolimus and/or concomitant medications during concurrent use <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>, <linkHtml href="#S6.2">6.2)</linkHtml> and <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="2d62fdd7-386e-4363-a2f8-d546273b9476"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.6 Neurotoxicity</title>
                     <text>
                        <paragraph>ENVARSUS XR may cause a spectrum of neurotoxicities. The most severe neurotoxicities include posterior reversible
encephalopathy syndrome (PRES), delirium, seizure, and coma; others include tremors, paresthesias, headache, mental
status changes, and changes in motor and sensory functions <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#S6.1">6.1</linkHtml>, <linkHtml href="#S6.2">6.2)</linkHtml>].</content> As symptoms may be
associated with tacrolimus whole blood trough concentrations at or above the recommended range, monitor for neurologic
symptoms and consider dosage reduction or discontinuation of ENVARSUS XR if neurotoxicity occurs.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="c30f32ce-15e4-4320-ac6f-f35c260f374f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.7 Hyperkalemia</title>
                     <text>
                        <paragraph>Mild to severe hyperkalemia, which may require treatment, has been reported with tacrolimus including ENVARSUS XR.
Concomitant use of agents associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin
receptor blockers) may increase the risk for hyperkalemia <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1</linkHtml>)].</content> Monitor serum potassium levels
periodically during treatment.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="d09f6151-5a7a-4c06-b484-0083af8fe46d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.8 Hypertension</title>
                     <text>
                        <paragraph>Hypertension is a common adverse reaction of ENVARSUS XR therapy and may require antihypertensive therapy <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Some antihypertensive drugs can increase the risk for hyperkalemia  <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>. Calcium-channel blocking agents may increase tacrolimus blood concentrations and require dosage reduction of ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="3320db33-dd6f-4161-8d2d-a238945dae0b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.9 Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. In contrast, the concomitant use of strong CYP3A inhibitors may decrease the metabolism of tacrolimus, leading to higher whole blood trough concentrations and greater risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) <content styleCode="Italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6</linkHtml>, <linkHtml href="#S5.10">5.10)</linkHtml>].</content> Therefore, adjust
ENVARSUS XR dose and monitor tacrolimus whole blood trough concentrations when co-administering ENVARSUS XR
with strong CYP3A inhibitors (e.g., including but not limited to telaprevir, boceprevir, ritonavir, ketoconazole,
itraconazole, voriconazole, clarithromycin) or strong CYP3A inducers (e.g., including but not limited to rifampin,
rifabutin) <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4</linkHtml>, <linkHtml href="#S2.5">2.5)</linkHtml>,      <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>. A rapid, sharp rise in tacrolimus levels has been reported after co-administration with strong CYP3A4 inhibitors despite an initial reduction of tacrolimus dose. Early and frequent monitoring of tacrolimus whole blood trough levels is recommended <content styleCode="Italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].</content>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="f6b2fba6-f11b-4027-8d70-f74c5d08cd0c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.10 QT Prolongation</title>
                     <text>
                        <paragraph>ENVARSUS XR may prolong the QT/QTc interval and cause <content styleCode="italics">Torsades de pointes</content>. Avoid ENVARSUS XR in patients
with congenital long QT syndrome. Consider obtaining electrocardiograms and monitoring electrolytes (magnesium,
potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking
certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances
(e.g., hypokalemia, hypocalcemia, or hypomagnesemia).</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">When co-administering ENVARSUS XR with other substrates and/or inhibitors of CYP3A, especially those that also have the potential to prolong the QT interval, a reduction in ENVARSUS XR dosage, monitoring of tacrolimus whole blood concentrations, and monitoring for QT prolongation is recommended <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="02d3ee99-5d80-4bd3-872a-9dd0eb29787c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.11 Immunizations</title>
                     <text>
                        <paragraph>Whenever possible, administer the complete complement of vaccines before transplantation and treatment with
ENVARSUS XR.</paragraph>
                        <paragraph>Avoid the use of live attenuated vaccines during treatment with ENVARSUS XR (e.g., intranasal influenza, measles,
mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines).</paragraph>
                        <paragraph>Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic during
treatment with ENVARSUS XR.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="6a880038-6c2e-44fd-b3d6-1d8be9a7d887"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">5.12 Pure Red Cell Aplasia</title>
                     <text>
                        <paragraph>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. All of these patients reported
risk factors for PRCA such as parvovirus B19 infection, underlying disease, or concomitant medications associated with
PRCA. A mechanism for tacrolimus-induced PRCA has not been elucidated. If PRCA is diagnosed, consider
discontinuation of ENVARSUS XR.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="17d37a97-138d-42a9-8e2e-8d72ecc6bb93"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.13 Cannabidiol Drug Interactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">When cannabidiol and ENVARSUS XR are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. A dose reduction of ENVARSUS XR should be considered as needed when ENVARSUS XR is co-administered with cannabidiol [<content styleCode="italics">see <linkHtml href="#S2.4">Dosage and Administration (2.4</linkHtml>, <linkHtml href="#S2.5">2.5)</linkHtml>, <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                              </content>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="ddcbe618-d93b-4358-a1ce-37e305339f63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Thrombotic Microangiopathy (TMA) Including Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Cases of thrombotic microangiopathy (TMA), including hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), have been reported in patients treated with ENVARSUS XR. TMA may have a multifactorial etiology. Risk factors for TMA that can occur in transplant patients include, for example, severe infections, graft-versus-host disease (GVHD), Human Leukocyte Antigen (HLA) mismatch, the use of calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors. These risk factors may, either alone or combined, contribute to the risk of TMA.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In patients with signs and symptoms of TMA, consider ENVARSUS XR as a risk factor. Concurrent use of ENVARSUS XR and mTOR inhibitors may contribute to the risk of TMA.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="d34bbd3f-cc8c-45bc-b9ca-6216fd06e337"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse drug reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Lymphoma and Other Malignancies <content styleCode="italics">[see <linkHtml href="#SBW">Boxed Warning, </linkHtml>
                           <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Serious Infections <content styleCode="italics">[see <linkHtml href="#SBW">Boxed Warning,</linkHtml>
                           <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>New Onset Diabetes after Transplant <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Nephrotoxicity due to ENVARSUS XR and Drug Interactions <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Neurotoxicity <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>Hyperkalemia <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Hypertension <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]</content>
                     </item>
                     <item>Pure Red Cell Aplasia <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>]</content>
                     </item>
                     <item>Thrombotic Microangiopathy, Including Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura <content styleCode="italics">[see <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>De novo kidney transplant patients: Most common adverse reactions
(incidence ≥15%) include: diarrhea, anemia, urinary tract infection,
hypertension, tremor, constipation, diabetes mellitus, peripheral edema,
hyperkalemia and headache. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>Conversion of kidney transplant patients from immediate-release to
extended-release tacrolimus: Most common adverse reactions (incidence
≥10%) include: diarrhea and blood creatinine increased. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Veloxis
Pharmaceuticals, Inc. at 1-844-VELOXIS (1-844-835-6947) or FDA at
1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="fe5befad-0304-4d15-9dad-a9fd4df662e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical
studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates
observed in practice. In addition, the clinical studies were not designed to establish comparative differences across study
arms with regards to the adverse reactions discussed below.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1- Phase 3 Clinical Study in De Novo Kidney Transplant Recipients</content>
                        </paragraph>
                        <paragraph>Study 1 (NCT 01187953), was a Phase 3 randomized study in de novo kidney transplant patients that were treated with
ENVARSUS XR (N=268) or tacrolimus [immediate-release] capsules (N=275) and concomitant immunosuppressants in a
double-blind, randomized, multinational study <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].</content> The proportion of patients who discontinued
treatment due to adverse reactions was 8.6% and 9.8% in the ENVARSUS XR and tacrolimus capsules treatment groups,
respectively, through 12 months of treatment. The most common adverse reactions leading to discontinuation of study
drug in the ENVARSUS XR treatment group were esophagitis, polyomavirus-associated nephropathy, graft dysfunction,
complications of transplanted kidney, and diabetes mellitus, each resulting in 0.7% discontinuations among ENVARSUS
XR treatment patients. In Study 1, de novo kidney transplant patients who received a starting dose of 0.17 mg/kg/day,
which is higher than the recommended ENVARSUS XR starting dose of 0.14 mg/kg/day, exceeded the recommended
target tacrolimus trough concentrations as high as 57 ng/mL during the first 1 to 2 weeks post-transplant <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections</content>
                        </paragraph>
                        <paragraph>The overall incidence of infections, serious infections, and infections with identified etiology reported in de novo kidney
transplant recipients treated with ENVARSUS XR or tacrolimus [immediate-release] capsules in Study 1 are shown in <content styleCode="bold">Table 2</content>.</paragraph>
                        <table width="750" styleCode="Noautorules" ID="table2">
                           <caption>Table 2 Percentage of Patients with Infections Through 1 Year Post-Kidney Transplant in Study 1 <sup>a</sup>
                           </caption>
                           <col width="40%"/>
                           <col width="30%"/>
                           <col width="30%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">MMF/MPS- Mycophenolate mofetil/mycophenolate sodium; AZA-azathioprine<br/>
                                    <br/>
                                    <sup>a</sup> Study 1 was not designed to support comparative claims of ENVARSUS XR compared to tacrolimus [immediate-release] capsules
for the adverse reactions reported in this table.</td>
                              </tr>
                              <tr>
                                 <td colspan="3">
                                    <sup>b</sup> BK virus-associated nephropathy (BKVAN) occurred in 1.5% (4/268) and 0.7% (2/275) in the ENVARSUS XR and tacrolimus
capsules treatment groups, respectively.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"/>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR ± steroids, IL-2 receptor antagonist induction therapy, MMF/MPS or AZA 
                                                                                                                                                                                                <br/>
                                    <br/>
                                                                                                                                                                                                N=268
                                                                                                                                                                                </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus [immediate-release]
capsules ±
steroids, IL-2 receptor
antagonist induction
therapy, MMF/MPS or
AZA<br/>
                                    <br/>
                                                                                                                                                                                                N=275
                                                                                                                                                                                </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> All infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">70%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">65%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Urinary Tract Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">29%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">27%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Respiratory Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">28%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">24%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Bacterial Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">18%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Cytomegalovirus Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">9%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Fungal Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">9%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             Gastrointestinal Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">             BK virus <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">9%</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">  Serious Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">26%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">24%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">New Onset Diabetes After Transplantation</content>
                        </paragraph>
                        <paragraph>New onset diabetes after transplantation (NODAT) was defined by the composite occurrence of fasting plasma glucose
values ≥126 mg/dL, 2-hour post-prandial plasma glucose of at least 200 mg/dL (in oral glucose tolerance test) on two or
more consecutive occasions post-baseline, insulin requirement for ≥31 days, an oral hypoglycemic agent use ≥31 days, or
HbA<sub>1c</sub> ≥6.5% (at least 3 months after randomization) among kidney transplant patients with no medical history of
diabetes. The incidence of NODAT for Study 1 through one year post-transplant is summarized in <content styleCode="bold">Table 3</content> below <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                        <table width="750" styleCode="Noautorules" ID="table3">
                           <caption>Table 3. Percentage of Patients with NODAT Through 1 Year Post-Kidney Transplant in Study 1 <sup>a</sup>
                           </caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">MMF/MPS- Mycophenolate mofetil/mycophenolate sodium; AZA-azathioprine<br/>
                                    <br/>
                                    <sup>a</sup> Study 1 was not designed to support comparative claims of ENVARSUS XR compared to tacrolimus [immediate-release] capsules
for the adverse reactions reported in this table.</td>
                              </tr>
                              <tr>
                                 <td colspan="3">
                                    <sup>b</sup> Analyses restricted to patients at risk for NODAT.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"/>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR ± steroids, IL-2 receptor antagonist induction therapy, MMF/MPS or AZA 
                                                                                                                                                                                                <br/>(N=88)
                                                                                                                                                                                </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus [immediate-release]
capsules ±
steroids, IL-2 receptor
antagonist induction
therapy, MMF/MPS or
AZA<br/>(N=74)
                                                                                                                                                                                </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Composite NODAT <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">21%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">15%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     HbA<sub>1c</sub> ≥6.5%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule"> 13% </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Fasting Plasma Glucose Values ≥126 mg/dL
on 2       consecutive occurrences</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Oral hypoglycemic use</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">7%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Insulin use ≥31 days</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1% </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>The incidence of adverse reactions that occurred in ≥10% of ENVARSUS XR-treated patients compared to tacrolimus
[immediate-release] capsules through one year of treatment in Study 1 is shown by treatment group in <content styleCode="bold">Table 4
                           </content>.</paragraph>
                        <table width="750" styleCode="Noautorules">
                           <caption>Table 4. Adverse Reactions ( ≥ 10%) in Kidney Transplant Patients Through 1 Year Post-Transplant in Study 1<sup>a</sup>
                           </caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> Study 1 was not designed to support comparative claims of ENVARSUS XR compared to tacrolimus [immediate-release] capsules
for the adverse reactions reported in this table.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" align="left" styleCode="Lrule Toprule Rrule Botrule bold"> Adverse Reaction</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR<br/>
                                                                                                                   N=268
                                                                                                          </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus [immediate-release]
capsules<br/>
                                                                                                                   N=275
                                                                                                          </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Diarrhea</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">31%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">34%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Anemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">26%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">29%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Urinary Tract Infection</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">25%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">25%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hypertension</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">23%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">23%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Tremor</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">19%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">17%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Constipation</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">18%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">25%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Diabetes Mellitus</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">16%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">14%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Peripheral Edema</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">16%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">21%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hyperkalemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">15%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Headache</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">15%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">10%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hypophosphatemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">15%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Leukopenia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">14%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Nausea</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">15%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Insomnia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Increased Blood Creatinine</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">14%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hypomagnesemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hypokalemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Hyperglycemia</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">12%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Study 2- Phase 2 Clinical Study in De Novo Kidney Transplant Recipients</content>
                        </paragraph>
                        <paragraph>Study 2 (NCT00765661) was an open-label Phase 2 study conducted in de novo kidney transplant patients randomized to
once daily ENVARSUS XR (N=32) or twice daily tacrolimus [immediate-release] capsules (N=31). The study was
conducted in the US and patients received an organ from a deceased or living donor. Pharmacokinetics were evaluated
during the first 2 weeks with an additional 50-week treatment and follow-up to evaluate safety and efficacy <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical
Studies (14.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The starting dosage was 0.14 mg/kg/day (given once daily) for ENVARSUS XR and 0.2 mg/kg/day (given twice daily)
for tacrolimus [immediate-release] capsules. On Day 2 predose, the proportion of patients in the ENVARSUS XR group
with tacrolimus trough concentration that were within, above, and below 6 to 11 ng/mL was 53%, 11%, and 37%,
respectively. The starting dose of 0.14 mg/kg/day in Study 2 formed the basis of dosing recommendations in de novo
kidney transplant patients.</paragraph>
                        <paragraph>There were no deaths or graft failures in Study 2. Two patients in each arm discontinued due to adverse events. The most
common adverse reactions included infections and cardiovascular events, and were generally similar to those reported in
Study 1.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 3- Phase 3 Clinical Studies in Stable Kidney Transplant Recipients Converted from Tacrolimus Capsules</content>
                        </paragraph>
                        <paragraph>In Study 3 (NCT00817206) stable kidney transplant patients were treated with ENVARSUS XR (N=162) or tacrolimus
[immediate-release] capsules (N=162) and concomitant immunosuppressants in an open-label, randomized, multinational
study <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>].</content> The proportion of patients who discontinued treatment due to adverse reactions was
7.4% and 1.2% in the ENVARSUS XR and tacrolimus capsules treatment groups, respectively, through 12 months of
treatment. The most common adverse reactions leading to discontinuation of study drug in the ENVARSUS XR treatment
group was cardiac arrest (2 events).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections</content>
                        </paragraph>
                        <paragraph>The overall incidence of infections, serious infections, and infections with identified etiology reported in stable kidney
transplant recipients treated with ENVARSUS XR or tacrolimus capsules are shown in <content styleCode="bold">Table 5.</content>
                        </paragraph>
                        <table width="750" styleCode="Noautorules" ID="table5">
                           <caption>Table 5. Percentage of Stable Patients with Infections Through 1 Year Post-Treatment in Study 3 <sup>a</sup>
                           </caption>
                           <col width="40%"/>
                           <col width="30%"/>
                           <col width="30%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">MMF/MPS- Mycophenolate mofetil/mycophenolate sodium; AZA-azathioprine <br/>
                                    <sup>a</sup> The stable kidney transplant study was not designed to support comparative claims of ENVARSUS XR compared to tacrolimus
capsules for the adverse reactions reported in this table.</td>
                              </tr>
                              <tr>
                                 <td colspan="3">
                                    <sup>b</sup> BK virus associated nephropathy (BKVAN) occurred in 1.2% (2/162) and 0.6% (1/162) in the ENVARSUS XR and tacrolimus
capsules treatment groups, respectively.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"> </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR ± steroids, MMF/MPS or AZA <br/>
                                    <br/>N=162</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus [immediate-release]
capsules±
steroids, MMF/MPS or
AZA<br/>
                                    <br/>N=162
											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">  All infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">46%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">48%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Respiratory Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">26%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">28%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Urinary Tract Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">10%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">14%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Bacterial Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">7%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Fungal Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Gastrointestinal Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       BK virus <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">       Cytomegalovirus Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1%</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">  Serious Infections</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">9%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">New Onset Diabetes After Transplantation</content>
                        </paragraph>
                        <paragraph>New onset diabetes after transplantation (NODAT) was defined by the composite occurrence of fasting plasma glucose
values ≥126 mg/dL, 2-hour postprandial plasma glucose of at least 200 mg/dL (in oral glucose tolerance test) on 2 or more
consecutive occasions post-baseline, insulin requirement for ≥31 days, an oral hypoglycemic agent use ≥31 days, or
HbA1c ≥6.5% (at least 3 months after randomization) among kidney transplant patients with no medical history of
diabetes. The incidence of NODAT for the stable kidney transplant study through one year post-transplant is summarized
in <content styleCode="bold">Table 6</content> below <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                        <table width="750" styleCode="Noautorules" ID="table6">
                           <caption>Table 6. Percentage of Stable Patients with NODAT Through 1 Year Post- Treatment in Study 3 <sup>a</sup>
                           </caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">MMF/MPS- Mycophenolate mofetil/mycophenolate sodium; AZA-azathioprine<br/>
                                    <sup>a</sup> The stable kidney transplant study was not designed to support comparative claims of ENVARSUS XR compared to tacrolimus capsules for the
adverse reactions reported in this table.</td>
                              </tr>
                              <tr>
                                 <td colspan="3">
                                    <sup>b</sup> Analyses restricted to patients at risk for NODAT.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"> </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR ± steroids, MMF/MPS or AZA 
												<br/>(N=90)
											</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus [immediate-release]
capsules ±
steroids, MMF/MPS or
AZA<br/>(N=95)
											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Composite NODAT <sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">10%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">        HbA<sub>1c</sub> ≥6.5%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">3%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">7%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Fasting Plasma Glucose Values ≥126 mg/dL<br/>      on 2 consecutive occurrences</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Oral hypoglycemic use</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Insulin use ≥31 days</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">0%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>In Study 3, the most common (≥10%) adverse reactions observed with Envarsus XR were diarrhea (14%), and blood
creatinine increased (12%).</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="6ff9ed13-6f99-40ca-b592-5f4d168f16c9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported from marketing experience with tacrolimus in the U.S. and outside
the U.S. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to
reliably estimate their frequency or establish a causal relationship to drug exposure. The following reactions have been
included due to either their seriousness, frequency of reporting or strength of causal connection to ENVARSUS XR:</paragraph>
                        <list listType="unordered">
                           <item>Blood and Lymphatic System Disorders: Agranulocytosis, decreased blood fibrinogen, disseminated intravascular coagulation, hemolytic anemia, hemolytic uremic syndrome, leukopenia, febrile neutropenia, pancytopenia, prolonged activated partial thromboplastin time, pure red cell aplasia  <content styleCode="italics">[see <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>]</content>, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombotic microangiopathy</item>
                           <item>Cardiac Disorders: Atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac arrest, electrocardiogram T wave abnormal, flushing, myocardial hypertrophy, myocardial infarction, myocardial ischaemia, pericardial effusion, QT prolongation, supraventricular extrasystoles, supraventricular tachycardia, <content styleCode="italics">Torsades de pointes</content>, deep limb venous thrombosis, ventricular fibrillation</item>
                           <item>Ear Disorders: Hearing loss including deafness</item>
                           <item>Eye Disorders: Blindness, optic neuropathy, photophobia, optic atrophy</item>
                           <item>Gastrointestinal Disorders: Abdominal pain, colitis, dysphagia, gastrointestinal perforation, impaired gastric emptying, intestinal obstruction, mouth ulceration, peritonitis, stomach ulcer</item>
                           <item>Hepatobiliary Disorders: Bile duct stenosis, cholangitis, cirrhosis, fatty liver, hepatic cytolysis, hepatic failure, hepatic necrosis, hepatic steatosis, jaundice, hemorrhagic pancreatitis, necrotizing pancreatitis, venoocclusive liver disease, hepatitis (acute and chronic)</item>
                           <item>Hypersensitivity Reactions:  Hypersensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</item>
                           <item>Immune System Disorders: Graft versus host disease (acute and chronic)</item>
                           <item>Metabolism and Nutrition Disorders: Glycosuria, increased amylase, pancreatitis</item>
                           <item>Musculoskeletal and Connective Tissue Disorders: Myalgia, polyarthritis, rhabdomyolysis</item>
                           <item>Neoplasms: Lymphoma including EBV-associated lymphoproliferative disorder, PTLD <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>; leukemia</item>
                           <item>Nervous System Disorders: Carpal tunnel syndrome, cerebral infarction, coma, dysarthria, flaccid paralysis, hemiparesis, mental disorder, mutism, nerve compression, posterior reversible encephalopathy syndrome (PRES) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>, progressive multifocal leukoencephalopathy (PML) sometimes fatal <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>, quadriplegia, speech disorder, status epilepticus, syncope </item>
                           <item>Renal and Urinary Disorder: Acute renal failure, hemorrhagic cystitis, hemolytic uremic syndrome, micturition disorder</item>
                           <item>Respiratory, Thoracic and Mediastinal Disorders: Acute respiratory distress syndrome, interstitial lung disease, lung
infiltration, pulmonary embolism, pulmonary hypertension, respiratory distress, respiratory failure</item>
                           <item>Skin and Subcutaneous Tissue Disorders: Hyperpigmentation, photosensitivity, pruritus, rash</item>
                        </list>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="846f5c5c-12a3-4cfb-8e9b-c33a689515d2"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Risk of rejection with strong CYP3A inducers and risk of serious adverse reactions with strong CYP3A inhibitors: Adjust dose and monitor tacrolimus concentrations. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.9">5.9</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>) </item>
                           <item>Therapeutic drug monitoring and dose reduction for ENVARSUS XR should be considered when ENVARSUS XR is co-administered with cannabidiol (<linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S5.13">5.13</linkHtml>, <linkHtml href="#S7.3">7.3</linkHtml>).</item>
                           <item>See Full Prescribing Information for clinically significant drug interactions. (<linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="23638184-5478-48d5-8dc6-ebdcc7d303c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">7.1 Mycophenolic Acid</title>
                     <text>
                        <paragraph>When ENVARSUS XR is prescribed with a given dose of mycophenolic acid (MPA) product, exposure to MPA is higher
with ENVARSUS XR co-administration than with cyclosporine co-administration with MPA, because cyclosporine
interrupts the enterohepatic recirculation of MPA while tacrolimus does not. Monitor for MPA associated adverse
reactions and reduce the dose of concomitantly administered MPA products as needed.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="f5094a3a-0b27-40d4-8d19-1a547f4d1625"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">7.2 Effects of Other Drugs/Substances on ENVARSUS XR</title>
                     <text>
                        <table width="750" styleCode="Noautorules" ID="table8">
                           <caption>Table 7. Effects of Other Drugs/Substances on ENVARSUS XR<sup>a, d</sup>
                           </caption>
                           <col width="35%"/>
                           <col width="30%"/>
                           <col width="35%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5">
                                    <sup>a</sup> ENVARSUS XR dosage adjustment recommendation based on observed effect of co-administered drug on tacrolimus exposures <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, literature reports of altered tacrolimus exposures, or the other drug’s known CYP3A inhibitor/inducer status<br/>
                                    <sup>b</sup> High dose or double strength grapefruit juice is a <content styleCode="italics">strong</content> CYP3A inhibitor; low dose or single strength grapefruit juice is a <content styleCode="italics">moderate</content> CYP3A inhibitor<br/>
                                    <sup>c</sup> Strong CYP3A inhibitor/inducer, based on reported effect on exposures to immediate-release tacrolimus along with supporting <content styleCode="italics">in vitro</content> CYP3A inhibitor/inducer data, or based on drug-drug interaction studies with midazolam (sensitive CYP3A probe substrate)
                                    <br/>
                                    <sup>d</sup> A drug interaction study with voriconazole was conducted for ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. No other drug-drug   interaction studies were conducted with ENVARSUS XR.  
                                    </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Drug/Substance Class or Name</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Drug Interaction Effect</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Recommendations</td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Grapefruit or grapefruit juice<sup>b</sup>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6</linkHtml>, <linkHtml href="#S5.9">5.9</linkHtml>, <linkHtml href="#S5.10"> 5.10)</linkHtml>].</content>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Avoid grapefruit or grapefruit juice.</td>
                              </tr>
                              <tr valign="top">
                                 <td valign="top" align="left" styleCode="Lrule Toprule Rrule Botrule"> Alcohol</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May modify  the rate of tacrolimus release.</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Avoid alcoholic beverages.</td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Strong CYP3A Inducers<sup>c,</sup> such as: <br/>    Antimycobacterials (e.g.,  <br/>    rifampin, rifabutin),  <br/>    anticonvulsants (e.g., phenytoin,  <br/>    carbamazepine and  <br/>    phenobarbital), St  John’s Wort</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May decrease tacrolimus whole blood trough concentrations and increase the risk of rejection <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>].</content>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Increase ENVARSUS XR dose and monitor tacrolimus whole blood trough concentrations <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Strong CYP3A Inhibitors<sup>c,</sup>, such as:<br/>    Protease inhibitors (e.g.,  <br/>    nelfinavir, telaprevir, boceprevir,     ritonavir  or ritonavir containing<br/>      products), azole antifungals (e.g.,  <br/>    voriconazole, posaconazole,  <br/>    itraconazole, ketoconazole),  <br/>    antibiotics (e.g., clarithromycin,  <br/>    troleandomycin, chloramphenicol),     nefazodone, <content styleCode="italics">Schisandra sphenanthera</content> extracts, cobicistat
											</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation). A rapid, sharp rise in tacrolimus levels may occur early, despite an immediate reduction of tacrolimus dose <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6,</linkHtml>
                                       <linkHtml href="#S5.9"> 5.9,</linkHtml>
                                       <linkHtml href="#S5.10"> 5.10)</linkHtml>].</content>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Reduce ENVARSUS XR dose (for voriconazole and posaconazole, give one-third of the original dose) and adjust dose based on tacrolimus whole blood trough concentrations <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>
                                        and <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>].</content> Early and frequent monitoring of tacrolimus whole blood trough levels should start within 1-3 days and continue monitoring as necessary <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)]</linkHtml>.</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Mild or Moderate CYP3A<br/> Inhibitors, such as:<br/>
												    antibiotics (e.g., erythromycin),  <br/>    calcium channel blockers (e.g.,  <br/>    verapamil, diltiazem, nifedipine,  <br/>    nicardipine), amiodarone,   <br/>    danazol, ethinyl estradiol,  <br/>    cimetidine, lansoprazole and  <br/>    omeprazole, azole antifungals  <br/>    (e.g., clotrimazole, fluconazole,     isavuconazole), imatinib, nilotinib,     letermovir    
											</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6</linkHtml>, <linkHtml href="#S5.9">5.9</linkHtml>, <linkHtml href="#S5.10"> 5.10)</linkHtml>].</content>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Monitor tacrolimus whole blood trough concentrations and reduce ENVARSUS XR dose if needed <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Other drugs, such as:<br/>
												    Magnesium and aluminum <br/>     hydroxide antacids<br/>
                                    <br/>
												    Metoclopramide
											</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May increase tacrolimus whole blood trough concentrations and increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6</linkHtml> and <linkHtml href="#S5.10"> 5.10)</linkHtml>].</content>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Monitor tacrolimus whole blood trough concentrations and reduce ENVARSUS XR dose if needed <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule"> Mild or Moderate CYP3A Inducers,<br/>  such as:<br/>
												    Methylprednisolone, prednisone
												<br/>
                                 </td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May decrease tacrolimus whole blood trough concentrations.</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Monitor tacrolimus whole blood trough concentrations and adjust ENVARSUS XR dose if needed <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr valign="top">
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Caspofungin</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">May decrease tacrolimus whole blood trough concentrations.</td>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule">Monitor tacrolimus whole blood trough concentrations and adjust ENVARSUS XR dose if needed <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>].</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Direct Acting Antiviral (DAA) Therapy</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of tacrolimus may be impacted by changes in liver function during DAA therapy, related to clearance of HCV virus. Close monitoring and potential dose adjustment of tacrolimus is warranted to ensure continued efficacy.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="b7ec1957-1c8f-4e42-af29-03a7c0f80c35"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Cannabidiol</title>
                     <text>
                        <paragraph>The blood levels of tacrolimus may increase upon concomitant use with cannabidiol. When cannabidiol and ENVARSUS XR are co-administered, closely monitor for an increase in tacrolimus blood levels and for adverse reactions suggestive of tacrolimus toxicity. A dose reduction of ENVARSUS XR should be considered as needed when ENVARSUS XR is co-administered with cannabidiol [<content styleCode="italics">see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="5f5b0e13-32ac-4faa-8619-b782575c4eb8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240416"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>­Pregnancy: Can cause fetal harm. Advise pregnant women of the potential risk
to the fetus. (<linkHtml href="#s8.1">8.1</linkHtml>, <linkHtml href="#s8.3">8.3</linkHtml>) 
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="93b24e8a-2b70-4e5d-8c5d-c8cc70d6c80c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy registry that monitors pregnancy outcomes in women exposed to ENVARSUS XR during pregnancy. The Transplantation Pregnancy Registry International (TPRI) is a voluntary pregnancy exposure registry that monitors outcomes of pregnancy in female transplant recipients and those fathered by male transplant recipients exposed to immunosuppressants including tacrolimus. Healthcare providers are  encouraged to advise their patients to register by contacting the Transplantation Pregnancy Registry International at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Tacrolimus can cause fetal harm when administered to a pregnant woman. Data from postmarketing surveillance and
TPRI suggest that infants exposed to tacrolimus in utero are at a risk of prematurity, birth defects/congenital anomalies,
low birth weight, and fetal distress <content styleCode="italics">[see Human Data].</content> Advise pregnant women of the potential risk to the fetus.</paragraph>
                        <paragraph>Administration of oral tacrolimus to pregnant rabbits and rats throughout the period of organogenesis was associated with
maternal toxicity/lethality, and an increased incidence of abortion, malformation and embryofetal death at clinically
relevant doses (0.7 to 3.7 times the recommended clinical dose [0.14 mg/kg/day], on a mg/m² basis). Administration of
oral tacrolimus to pregnant rats after organogenesis and throughout lactation produced maternal toxicity, effects on
parturition, reduced pup viability and reduced pup weight at clinically relevant doses (1.2 to 3.7 times the recommended
clinical dose, on a mg/m² basis). Administration of oral tacrolimus to rats prior to mating, and throughout gestation and
lactation produced maternal toxicity/lethality, marked effects on parturition, embryofetal loss, malformations, and reduced
pup viability at clinically relevant doses (1.2 to 3.7 times the recommended clinical dose, on a mg/m² basis). Interventricular septal defects, hydronephrosis, craniofacial malformations and skeletal effects were observed in offspring
that died <content styleCode="italics">[see Animal Data].</content>
                        </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage in the indicated population is unknown. In the U.S. general
population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2
to 4 % and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo-Fetal Risk</content>
                        </paragraph>
                        <paragraph>Risks during pregnancy are increased in organ transplant recipients.</paragraph>
                        <paragraph>The risk of premature delivery following transplantation is increased. Pre-existing hypertension and diabetes confer
additional risk to the pregnancy of an organ transplant recipient. Pre-gestational and gestational diabetes are associated
with birth defects/congenital anomalies, hypertension, low birth weight and fetal death.</paragraph>
                        <paragraph>Cholestasis of pregnancy (COP) was reported in 7% of liver or liver-kidney (LK) transplant recipients, compared with
approximately 1% of pregnancies in the general population. However, COP symptoms resolved postpartum and no long-term
effects on the offspring were reported.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maternal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>ENVARSUS XR may increase hyperglycemia in pregnant women with diabetes (including gestational diabetes). Monitor
maternal blood glucose levels regularly <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>ENVARSUS XR may exacerbate hypertension in pregnant women and increase pre-eclampsia. Monitor and control blood
pressure <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7</linkHtml>, <linkHtml href="#S5.8">5.8)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Renal dysfunction, transient neonatal hyperkalemia and low birth weight have been reported at the time of delivery in
infants of mothers taking ENVARSUS XR.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Labor or Delivery</content>
                        </paragraph>
                        <paragraph>There is an increased risk for premature delivery (&lt;37 weeks) following transplantation and maternal exposure to
ENVARSUS XR.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>There are no adequate and well controlled studies on the effects of tacrolimus in human pregnancy.</paragraph>
                        <paragraph>Safety data from the TPRI and postmarketing surveillance suggest infants exposed to tacrolimus in utero have an
increased risk for miscarriage, pre-term delivery (&lt;37 weeks), low birth weight (&lt;2500 g), birth defects/congenital
anomalies and fetal distress.</paragraph>
                        <paragraph>TPRI reported 450 and 241 total pregnancies in kidney and liver transplant recipients exposed to tacrolimus,
respectively. The TPRI pregnancy outcomes are summarized in <content styleCode="bold">Table 8.</content> In the table below, the number of recipients
exposed to tacrolimus concomitantly with mycophenolic acid (MPA) products during the preconception and first trimester
periods is high (27% and 29% for renal and liver transplant recipients, respectively). Because MPA products may also
cause birth defects, the birth defect rate may be confounded and this should be taken into consideration when reviewing
the data, particularly for birth defects. Birth defects observed include cardiac malformations, craniofacial malformations,
renal/urogenital disorders, skeletal abnormalities, neurological abnormalities and multiple malformations.</paragraph>
                        <table width="750" styleCode="Noautorules">
                           <caption>Table 8. TPRI Reported Pregnancy Outcomes in Transplant Recipients with Exposure to Tacrolimus</caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"> </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Kidney</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Liver</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">Pregnancy Outcomes*</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">462</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">253</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">  Miscarriage</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">24.5%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">25%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">  Live births</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">331</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">180</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Pre-term delivery (&lt; 37 weeks)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">49%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">42%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Low birth weight (&lt; 2500 g)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">42%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">30%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">     Birth defects</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8%†</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>*</sup>Includes multiple births and terminations.<br/>
                           <sup>†</sup>Birth defect rate confounded by concomitant MPA products exposure in over half of offspring with birth defects. </paragraph>
                        <paragraph>Additional information reported by TPRI in pregnant transplant patients receiving tacrolimus included diabetes during
pregnancy in 9% of kidney recipients and 13% of liver recipients and hypertension during pregnancy in 53% of kidney
recipients and 16.2% of liver recipients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Administration of oral tacrolimus to pregnant rabbits throughout organogenesis produced maternal toxicity and abortion at
0.32 mg/kg (0.7 times the recommended clinical dose based on body surface area). At 1 mg/kg (2.3 times the
recommended clinical dose) embryofetal lethality and fetal malformations (ventricular hypoplasia, interventricular septal
defect, bulbous aortic arch, stenosis of ductus arteriosus, omphalocele, gallbladder agenesis, skeletal anomalies) were
observed. Administration of 3.2 mg/kg oral tacrolimus (3.7 times the recommended clinical dose) to pregnant rats
throughout organogenesis produced maternal toxicity/lethality, embryofetal lethality and decreased fetal body weight in
the offspring of C-sectioned dams; and decreased pup viability and interventricular septal defect in offspring of dams that
delivered.</paragraph>
                        <paragraph>In a peri/postnatal development study, oral administration of tacrolimus to pregnant rats during late gestation (after
organogenesis) and throughout lactation produced maternal toxicity, effects of parturition, and reduced pup viability at
3.2 mg/kg (3.7 times the recommended clinical dose); among these pups that died early, an increased incidence of kidney
hydronephrosis was observed. Reduced pup weight was observed at 1mg/kg (1.2 times the recommended clinical dose).</paragraph>
                        <paragraph>Administration of oral tacrolimus to rats prior to mating, and throughout gestation and lactation produced maternal
toxicity/lethality, embryofetal loss and reduced pup viability at 3.2 mg/kg (3.7 times the recommended clinical dose).
Interventricular septal defects, hydronephrosis, craniofacial malformations and skeletal effects were observed in offspring
that died. Effects on parturition (incomplete delivery of nonviable pups) were observed at 1 mg/kg (1.2 times the
recommended clinical dose) <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="d5b2ff63-3c56-465b-acc0-a6fc4428b3c3"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Controlled lactation studies have not been conducted in humans; however tacrolimus has been reported to be present in
human milk. The effects of tacrolimus on the breastfed infant, or on milk production have not been assessed. Tacrolimus is
excreted in rat milk and in peri-/postnatal rat studies, exposure to tacrolimus during the postnatal period was associated with
developmental toxicity in the offspring at clinically relevant doses <content styleCode="italics">[see <linkHtml href="#S8.1">Pregnancy (8.1)</linkHtml>, <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for
ENVARSUS XR and any potential adverse effects on the breastfed child from ENVARSUS XR or from the underlying
maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="ed612794-0a53-404c-ada2-e3fa224effde"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>ENVARSUS XR can cause fetal harm when administered to pregnant women. Advise female and male patients of
reproductive potential to speak with their healthcare provider on family planning options including appropriate
contraception prior to starting treatment with ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>, <linkHtml href="#S13.1">Nonclinical
Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Based on findings in animals, male and female fertility may be compromised by treatment with ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="74cdf586-92f4-4ab5-beb6-ed7454e3b802"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ENVARSUS XR in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="b8706489-cede-4557-bf8a-0c5d818fa75a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ENVARSUS XR did not include sufficient numbers of patients aged 65 and over to determine whether
they respond differently from younger patients. In Studies 1, 2 and 3, there were 37 patients 65 years of age and older,
and no patients were over 75 years <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Other reported clinical experience has not identified
differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should
be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,
renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="0b57ff1b-24c2-443d-80fa-2b9e52d85b29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The pharmacokinetics of tacrolimus in patients with renal impairment was similar to that in healthy subjects with normal renal function. However, due to its potential for nephrotoxicity, monitoring of renal function in patients with renal impairment is recommended; tacrolimus dosage should be reduced if indicated <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="ab38b33a-a397-4f15-a643-0f9d52fabd78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>The mean clearance of tacrolimus was substantially lower in patients with severe hepatic impairment (mean Child-Pugh score: &gt;10) compared to healthy subjects with normal hepatic function <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. With greater tacrolimus whole blood trough concentrations in patients with severe hepatic impairment, there is a greater risk of adverse reactions and dosage reduction is recommended <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>. For patients with moderate hepatic impairment, monitor tacrolimus whole blood trough concentrations.  For patients with mild hepatic impairment, no dosage adjustments are needed.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.8">
                     <id root="d954cced-e8dd-48df-b085-ad9a761b50e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">8.8 Race</title>
                     <text>
                        <paragraph>African-American patients may need to be titrated to higher ENVARSUS XR dosages to attain comparable trough
concentrations compared to Caucasian patients. The pharmacokinetics of ENVARSUS XR were evaluated in a study of
46 stable African-American kidney transplant recipients converted from tacrolimus immediate-release to ENVARSUS
XR and indicated that an 80% conversion factor is appropriate for African-American patients <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and
Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>African-American and Hispanic kidney transplant patients are at an increased risk for new onset diabetes after transplant.
Monitor blood glucose concentrations and treat appropriately <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="2cbfbf78-b94a-4df1-a752-0fcb93f9dfc9"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title mediaType="text/x-hl7-title+xml">10 OVERDOSAGE</title>
               <text>
                  <paragraph>Postmarketing cases of overdose with tacrolimus have been reported. Overdosage adverse reactions included:</paragraph>
                  <list>
                     <item>nervous system disorders (tremor, headache, confusional state, balance disorders, encephalopathy, lethargy and
somnolence)</item>
                     <item>gastrointestinal disturbances (nausea, vomiting, and diarrhea)</item>
                     <item>abnormal renal function (increased blood urea nitrogen and elevated serum creatinine)</item>
                     <item>urticaria</item>
                     <item>hypertension</item>
                     <item>peripheral edema, and </item>
                     <item>infections (one fatal postmarketing case of bilateral pneumopathy and CMV infection was attributed to
tacrolimus extended-release capsules overdose).</item>
                  </list>
                  <paragraph>Based on the poor aqueous solubility and extensive erythrocyte and plasma protein binding, it is anticipated that
tacrolimus is not dialyzable to any significant extent; there is no experience with charcoal hemoperfusion. The oral use of
activated charcoal has been reported in treating acute overdoses, but experience has not been sufficient to warrant
recommending its use. General supportive measures and treatment of specific symptoms should be followed in all cases of
overdosage.</paragraph>
               </text>
               <effectiveTime value="20240416"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="f3266119-51fe-4aed-ac13-ce9b3ecd11c9"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title mediaType="text/x-hl7-title+xml">11 DESCRIPTION</title>
               <text>
                  <paragraph>Tacrolimus is the active ingredient in ENVARSUS XR. Tacrolimus is a calcineurin-inhibitor immunosuppressant produced by <content styleCode="italics">Streptomyces tsukubaensis.</content> Chemically, tacrolimus is designated as [3<content styleCode="italics">S</content>-[3<content styleCode="italics">R</content>*[<content styleCode="italics">E</content>(1<content styleCode="italics">S</content>*,3<content styleCode="italics">S</content>*,4<content styleCode="italics">S</content>*)],4<content styleCode="italics">S</content>*,5<content styleCode="italics">R</content>*,8<content styleCode="italics">S</content>*,9<content styleCode="italics">E</content>,12<content styleCode="italics">R</content>*,14<content styleCode="italics">R</content>*,15<content styleCode="italics">S</content>*,16<content styleCode="italics">R</content>*,18<content styleCode="italics">S</content>*,19<content styleCode="italics">S</content>*,26a<content styleCode="italics">R</content>*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclo-hexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-<content styleCode="italics">c</content>][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone, monohydrate.</paragraph>
                  <paragraph>The chemical structure of tacrolimus is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM160"/>
                  </paragraph>
                  <paragraph>Tacrolimus has an empirical formula of C<sub>44</sub>H<sub>69</sub>NO<sub>12</sub>•H<sub>2</sub>O and a formula weight of 822.03. Tacrolimus appears as white crystals or crystalline powder. It is practically insoluble in water, freely soluble in ethanol, and very soluble in methanol
and chloroform.</paragraph>
                  <paragraph>ENVARSUS XR is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg,
1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF,
polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and
dimethicone NF.</paragraph>
               </text>
               <effectiveTime value="20240416"/>
               <component>
                  <observationMedia ID="MM160">
                     <text>chemical-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-figure-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="cc79a650-67eb-42d8-aa54-8c9826ac6858"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240416"/>
               <component>
                  <section ID="S12.1">
                     <id root="29c727ce-612e-43af-8ebe-ff737f04d557"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and
calcineurin (an ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin
inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of
activated T-cells (NF-AT) and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB).</paragraph>
                        <paragraph>Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, tumor necrosis factor-alpha, and granulocyte macrophage colony stimulating factor. Tacrolimus also inhibits IL-2 receptor expression and nitric oxide release, induces apoptosis and
production of transforming growth factor-beta that can lead to immunosuppressive activity. The net result is the inhibition
of T-lymphocyte activation and proliferation as well as T-helper-cell-dependent B-cell response (i.e.,
immunosuppression).</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="4443b0d5-eb65-45c5-ab67-144cb788e0eb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <linkHtml href="#table9">Table 9</linkHtml>
                           </content> summarizes the pharmacokinetic (PK) parameters of tacrolimus following oral administration of once-daily ENVARSUS XR in healthy subjects and in kidney transplant patients, under fasted conditions. Whole blood tacrolimus concentrations in the pharmacokinetic studies were measured using validated HPLC/MS/MS assays.</paragraph>
                        <table width="750" styleCode="Noautorules" ID="table9">
                           <caption>Table 9. Pharmacokinetic Parameters of ENVARSUS XR by Study Day in Healthy Subjects and Kidney
Transplant Patients Under Fasted Conditions</caption>
                           <col width="20%"/>
                           <col width="14%"/>
                           <col width="10%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="7">a) Healthy adult subjects (administered mg/day dose); Adult <content styleCode="italics">de novo</content> kidney transplant patients (group average of administered mg/day dose); Adult kidney ≥ 6 months post-transplant (group average of administered mg/day dose of ENVARSUS XR, following conversion to 67% to 80% of the daily tacrolimus immediate -release capsules dose)<br/>
										b)	Day of ENVARSUS XR dosing and PK profiling<br/>
										c)	Arithmetic means ± S.D.<br/>
										d)	Median [range]<br/>
										e)	“<content styleCode="italics">De novo</content>” refers to immunosuppression starting at the time of transplantation<br/>
										f)	Starting ENVARSUS XR dose = 0.14 mg/kg/day<br/>
										g) Starting ENVARSUS XR dose = 0.17 mg/kg/day. <content styleCode="italics">De novo</content> kidney transplant patients who received ENVARSUS XR starting dose of 0.17
mg/kg/day achieved higher than recommended target tacrolimus trough concentrations, as high as 57 ng/mL during the first 1 to 2 weeks post-transplant.<br/>
										h)	Tacrolimus trough concentration before the next dose<br/>
										i)	After 7 days of stable dosing with ENVARSUS XR<br/>
										j)	AUC<sub>0-24</sub> –to- C<sub>24</sub> correlation coefficient (r) at steady state was 0.80 or higher<br/>
                                        k)	Conversion to ENVARSUS XR at a mean dose of 80% of the total daily dose of tacrolimus immediate-release resulted in equivalent exposure with a 30% reduction in C<sub>max</sub>.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Toprule Rrule" rowspan="2">
                                    <content styleCode="bold">Population</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule" rowspan="2">
                                    <content styleCode="bold">ENVARSUS<br/>XR Dose
                                    </content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule" rowspan="2">
                                    <content styleCode="bold">Day<sup>b</sup>
                                    </content>
                                 </td>
                                 <td colspan="4" align="center" styleCode="Lrule Botrule Rrule Toprule">
                                    <content styleCode="bold">Pharmacokinetic Parameters of ENVARSUS XR</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">C<sub>max</sub>
                                       <sup>c</sup>
                                       <br/>(ng/mL)</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">T<sub>max</sub>
                                       <sup>d</sup>
                                       <br/>(hr)</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">AUC<sub>24</sub>
                                       <sup>c</sup>
                                       <br/>(ng•hr/mL)</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">
                                    <content styleCode="bold">C<sub>24</sub>
                                       <sup>h</sup>
                                       <br/>(ng/mL)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Healthy Subjects<sup>a</sup>
                                    <br/>(n=19)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">2 mg<br/>2 mg</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Day 1<br/>Day 10</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11.9 ± 3.8<br/>8.3 ± 2.9</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">14.0 [6 - 28]<br/>8.0 [1.0-12.0]</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">50 ± 14<br/>140 ± 50</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1.8 ± 0.6<br/>4.6 ± 1.7</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Adult Kidney<sup>a</sup>
                                    <br/>
                                    <content styleCode="italics">De novo</content>
                                    <sup>e</sup> (n=21)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">11.8 mg <sup>f</sup>
                                    <br/>10 mg <br/>9.5 mg</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Day 1<br/>Day 7<br/>Day 14</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11.8 ± 7.2<br/>25.1 ± 16.3<br/>27.1 ± 13.4</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8.0 [4-24]<br/>6.0 [2-12]<br/>4.0 [1-8]</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">138 ± 80<br/>335 ± 129<br/>371 ± 104</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5.2 ± 2.7<br/>9.9 ± 4.4<br/>11.4 ± 4.1<sup>j</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Adult Kidney<sup>a</sup>
                                    <br/>
                                    <content styleCode="italics">De novo</content> (n=10)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">15.5 mg <sup>g</sup>
                                    <br/>11.4 mg <br/>11.1 mg</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Day 1<br/>Day 14<br/>Day 28</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">33.6 ± 21.8<br/>31.1 ± 14.6<br/>35.9± 18.7</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6.0 [4-24]<br/>4.0 [1-18]<br/>4.0 [1-14]</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">377 ± 257<br/>376 ± 140<br/>396 ± 150</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11.0 ± 6.1<br/>9.1 ± 3.0<br/>10.5 ± 3.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Adult Kidney<sup>a</sup>
                                    <br/>(≥ 6 months post-<br/>transplant) (n=47)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">5.3 mg</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Day 7<sup>i</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">13.5 ± 4.8</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">6.0 [1 - 16]</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">216 ± 63</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">7.0 ± 2.3 <sup>j</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Adult African-<br/>American Kidney<sup>k</sup>
                                    <br/>(≥ 6 months post-transplant) (n=46)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">7.8 mg</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Day 7<sup>i</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">18.4 ± 7.2</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5.0 [1 - 16]</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">272 ± 97</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">7.8 ± 2.9 <sup>j</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In de novo adult kidney transplant patients, the administration of ENVARSUS XR once daily at a starting dose of
0.14 mg/kg/day results in a tacrolimus systemic exposure (AUC<sub>24</sub>) on Day 1 post-transplant that is up to 10% lower than
that of tacrolimus immediate-release capsules twice daily administered at a starting dose of 0.1 mg/kg/day, while similar
tacrolimus trough concentrations (C<sub>24</sub>) are achieved. As steady state is achieved (typically within 7 days of stable
ENVARSUS XR dosing), the AUC<sub>24</sub> of ENVARSUS XR is approximately 15% higher than that of tacrolimus immediate-release
capsules, at comparable trough concentrations (C<sub>24</sub>).</paragraph>
                        <paragraph>In adult kidney transplant patients ≥ 6 months post-transplant switched to ENVARSUS XR at 67% to 80% of the daily
dose of tacrolimus immediate-release capsules, the steady state tacrolimus exposures (AUC<sub>24</sub>) and tacrolimus trough
concentrations (C<sub>24</sub>) were comparable to the AUC<sub>24</sub> and C<sub>24</sub> measured prior to the switch. However, the mean C<sub>max</sub>
estimate was 30% lower and the median T<sub>max</sub> was more prolonged (6 hours versus 2 hours) following administration of
Envarsus XR as compared to that of tacrolimus immediate-release capsules.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. In de novo
kidney transplant patients, the median time to achieve maximum blood concentrations (C<sub>max</sub>) of ENVARSUS XR was
approximately 6 to 10 hours (T<sub>max</sub>) on day 1 post-transplant; the median T<sub>max</sub> at steady state was 4 to 6 hours. In healthy
subjects, the oral bioavailability of ENVARSUS XR was approximately 50% higher as compared with both tacrolimus
immediate-release and extended-release capsule formulations at steady state. In healthy subjects who received single
ENVARSUS XR doses ranging from 5 mg to 10 mg, the mean AUC and C<sub>24</sub> of tacrolimus increased linearly and the
elimination half-life did not change with increasing doses.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Food Effects </content>
                        </paragraph>
                        <paragraph>The presence of a meal affects the absorption of tacrolimus; the rate and extent of absorption is greatest under fasted
conditions. In 26 healthy subjects, administration of ENVARSUS XR following a high-fat breakfast reduced the systemic
exposure (AUC) to tacrolimus by approximately 55% and the peak plasma concentration of tacrolimus (C<sub>max</sub>) by 22%,
with no effect on the time to reach maximum plasma concentration (T<sub>max</sub>), compared to when ENVARSUS XR was
administered under fasted conditions. ENVARSUS XR tablets should be taken preferably on an empty stomach at least 1
hour before a meal or at least 2 hours after a meal.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Chronopharmacokinetic Effect</content>
                        </paragraph>
                        <paragraph>In 26 healthy subjects, administration of ENVARSUS XR tablets in the evening resulted in a 15% lower AUC<sub>0-inf</sub> and a
20% lower C<sub>24</sub>, as compared to morning dosing.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The plasma protein binding of tacrolimus is approximately 99% and is independent of concentration over a range of 5-50
ng/mL. Tacrolimus is bound mainly to albumin and alpha-1-acid glycoprotein, and has a high level of association with
erythrocytes. The distribution of tacrolimus between whole blood and plasma depends on several factors, such as
hematocrit, temperature at the time of plasma separation, drug concentration, and plasma protein concentration. In a U.S.
trial in which tacrolimus was administered as immediate-release formulation, the ratio of whole blood concentration to
plasma concentration averaged 35 (range 12 to 67).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>The desired pharmacological activity of tacrolimus is primarily due to the parent drug. Tacrolimus is extensively
metabolized by the mixed-function oxidase system, primarily the cytochrome P-450 system 3A (CYP3A4 and CYP3A5). A metabolic
pathway leading to the formation of 8 possible metabolites has been proposed. Demethylation and hydroxylation were
identified as the primary mechanisms of biotransformation in vitro. The major metabolite identified in incubations with
human liver microsomes is 13-demethyl tacrolimus. In in vitro studies, a 31-demethyl metabolite has been reported to
have the same activity as tacrolimus.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>In a mass balance study of orally administered radiolabeled tacrolimus to 6 healthy subjects, the mean recovery of the
radiolabel was 94.9 ± 30.7%. Fecal elimination accounted for 92.6 ± 30.7% and urinary elimination accounted for 2.3 ±
1.1% of the total radiolabel administered. The elimination half-life based on radioactivity was 31.9 ± 10.5 hours, whereas
it was 48.4 ± 12.3 hours based on tacrolimus concentrations. The mean clearance of radiolabel was 0.226 ± 0.116 L/hr/kg
and the mean clearance of tacrolimus was 0.172 ± 0.088 L/hr/kg.</paragraph>
                        <paragraph>The elimination half-life of tacrolimus after oral administration of 2 mg ENVARSUS XR once-daily for 10 days was 31.0
± 8.1 hours (mean ± SD) in 25 healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients With Renal Impairment</content>
                        </paragraph>
                        <paragraph>Tacrolimus pharmacokinetics following a single administration of tacrolimus (administered as a continuous IV infusion)
were determined in 12 patients (7 not on dialysis and 5 on dialysis, serum creatinine of 3.9±1.6 and 12.0±2.4 mg/dL,
respectively) prior to their kidney transplant. The mean clearance of tacrolimus in patients with renal dysfunction given
IV tacrolimus was similar to that in healthy subjects given tacrolimus IV and in healthy subjects given oral tacrolimus
immediate-release <content styleCode="italics">[see <linkHtml href="#S8.6">Use In Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients With Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Tacrolimus pharmacokinetics have been determined in 6 patients with mild hepatic impairment (mean Pugh score: 6.2) following single oral administration of tacrolimus immediate-release. The mean clearance of tacrolimus in patients with mild hepatic impairment was not substantially different from that in healthy subjects. Tacrolimus pharmacokinetics were studied in 6 patients with severe hepatic impairment (mean Pugh score: &gt;10). The mean clearance was substantially lower in patients with severe hepatic impairment <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S8.7"> Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial or Ethnic Groups</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of ENVARSUS XR were evaluated in a study of 46 stable African American kidney transplant recipients converted from tacrolimus immediate-release to ENVARSUS XR. Approximately 80% of the African American patients were carriers of the active, wild type CYP3A5<sup>*</sup>1 allele. Regardless of genotype status, the PK results demonstrated similar exposure, lower C<sub>max</sub>, prolonged T<sub>max</sub>, and increased bioavailability compared to tacrolimus immediate-release  <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S8.8"> Use in Specific Populations (8.8)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients</content>
                        </paragraph>
                        <paragraph>A formal trial to evaluate the effect of gender on tacrolimus pharmacokinetics has not been conducted. In a sub-group analysis from the two combined Phase 3 studies in kidney transplant recipients (Study 1 and Study 3) performed with ENVARSUS XR over one year of treatment, no gender-dependent differences in tacrolimus systemic exposures were observed.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Because tacrolimus is metabolized mainly by CYP3A enzymes, drugs or substances known to inhibit these enzymes and/or are known CYP3A substrates may increase tacrolimus whole blood concentrations. Drugs known to induce CYP3A enzymes may decrease tacrolimus whole blood concentrations <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml> and <linkHtml href="#S7.2"> Drug Interactions (7.2)</linkHtml>]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Voriconazole:</content> Co-administration of ENVARSUS XR with voriconazole following 400 mg BID of voriconazole resulted in a tacrolimus mean AUC<sub>inf</sub> increase by 2.62 fold and C<sub>max</sub> by 2.03 fold.   </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="5015e2cf-8398-4f63-b5a2-5e33e73ea88f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title mediaType="text/x-hl7-title+xml">13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240416"/>
               <component>
                  <section ID="S13.1">
                     <id root="15d972b1-33e8-4225-822b-192c06fda3c4"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Carcinogenicity studies were conducted in male and female rats and mice. In the 80-week mouse oral study and in the 104-week rat oral study, no relationship of tumor incidence to tacrolimus dosage was found. The highest dose used in the mouse was 3mg/kg/day (0.84 times the AUC at the recommended clinical dose of 0.14 mg/kg/day ) and in the rat was 5 mg/kg/day (0.24 times the AUC at the recommended clinical dose of 0.14 mg/kg/day) <content styleCode="italics">[see <linkHtml href="#SBW">Boxed Warning</linkHtml> and <linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>A 104-week dermal carcinogenicity study was performed in mice with tacrolimus ointment (0.03%-3%), equivalent to
tacrolimus doses of 1.1-118 mg/kg/day or 3.3-354 mg/m<sup>2</sup>/day. In the study, the incidence of skin tumors was minimal and
the topical application of tacrolimus was not associated with skin tumor formation under ambient room lighting. However,
a statistically significant elevation in the incidence of pleomorphic lymphoma in high-dose male (25/50) and female
animals (27/50) and in the incidence of undifferentiated lymphoma in high-dose female animals (13/50) was noted in the
mouse dermal carcinogenicity study. Lymphomas were noted in the mouse dermal carcinogenicity study at a daily dose of
3.5 mg/kg (0.1% tacrolimus ointment; 2.5-fold the human exposure in stable adult renal transplant patients converted from tacrolimus immediate-release product to ENVARSUS XR). No drug-related tumors were noted in the mouse dermal
carcinogenicity study at a daily dose of 1.1 mg/kg (0.03% tacrolimus ointment). The relevance of topical administration of
tacrolimus in the setting of systemic tacrolimus use is unknown.</paragraph>
                        <paragraph>The implications of these carcinogenicity studies are limited; doses of tacrolimus were administered that likely induced
immunosuppression in these animals, impairing their immune system’s ability to inhibit unrelated carcinogenesis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>No evidence of genotoxicity was seen in bacterial (<content styleCode="italics">Salmonella</content> and <content styleCode="italics">E. coli</content>) or mammalian (Chinese hamster lung-derived cells) <content styleCode="italics">in vitro</content> assays of mutagenicity, the <content styleCode="italics">in vitro</content> CHO/HGPRT assay of mutagenicity, or <content styleCode="italics">in vivo</content> clastogenicity assays performed in mice; tacrolimus did not cause unscheduled DNA synthesis in rodent hepatocytes.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Tacrolimus subcutaneously administered to male rats at paternally toxic doses of 2 mg/kg/day (2.3 times the
recommended clinical dose based on body surface area) or 3 mg/kg/day (3.4 times the recommended clinical dose based
on body surface area) resulted in a dose-related decrease in sperm count. Tacrolimus administered orally at 1mg/kg (1.2
times the recommended clinical dose based on body surface area) to male and female rats, prior to and during mating, as
well as to dams during gestation and lactation, was associated with embryolethality and adverse effects on female
reproduction. Effects on female reproductive function (parturition) and embryolethal effects were indicated by a higher
rate of pre- and post-implantation loss and increased numbers of undelivered and nonviable pups. When administered at
3.2 mg/kg (3.7 times the recommended clinical dose based on body surface area), tacrolimus was associated with maternal
and paternal toxicity as well as reproductive toxicity including marked adverse effects on estrus cycles, parturition, pup
viability, and pup malformations.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="dc5e5944-71ce-4b29-914b-7337bcbcb792"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title mediaType="text/x-hl7-title+xml">14 CLINICAL STUDIES</title>
               <effectiveTime value="20240416"/>
               <component>
                  <section ID="S14.1">
                     <id root="128a60f8-789d-47f0-9517-bed69fd055fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">14.1 Clinical Studies in De Novo Kidney Transplant Recipients</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 1</content>
                        </paragraph>
                        <paragraph>Study 1 (NCT 01187953) was a Phase 3, 12-month, randomized, double-blind, multinational study comparing once daily ENVARSUS XR (N=268) to twice daily tacrolimus [immediate-release] capsules (N=275) in patients who received a de novo kidney transplant. Patients received the first dose of the study drug anytime within 48 hours of graft reperfusion. All patients received only IL-2 receptor antagonist induction therapy and concomitant treatment with mycophenolate mofetil (MMF) and corticosteroids. Approximately 97% of all patients received antibody induction therapy with basiliximab and 91% of all patients received corticosteroids and MMF.</paragraph>
                        <paragraph>The mean age of the study population was 46 years; 65% were male; 77% were Caucasian, 5% were African-American, 4% were Asian and 14% were categorized as other races. Living donors provided 49% of the organs and 51% of patients received a kidney transplant from a deceased donor. Patients with clinically relevant ECG abnormalities (including QTc prolongation and reversible ischemia) and clinically symptomatic congestive heart failure or patients with documented left ventricular ejection fraction of less than 45% were excluded. Patients with a panel reactive antibody (PRA) &gt;30%, who received a kidney from a non-heart-beating donor or with cold ischemia time &gt;30 hours were also excluded. Premature discontinuation from treatment at the end of one year occurred in 22% of ENVARSUS XR patients and 19% of tacrolimus [immediate-release] capsules patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tacrolimus Therapy</content>
                        </paragraph>
                        <paragraph>In Study 1, de novo kidney transplant patients were dosed initially at a starting dosage of 0.17 mg/kg given once daily for ENVARSUS XR (approximately 1.2-fold higher than the recommended starting dosage) and 0.1 mg/kg/day (given twice daily) for tacrolimus [immediate-release] capsule, with doses then modified to maintain tacrolimus trough concentrations between 6-11 ng/mL for the first 30 days and then between 4-11 ng/L for the remainder of the study. In the first week of dosing, the tacrolimus doses administered were, on average, ~40% higher in the ENVARSUS XR group compared to the tacrolimus capsule group and were similar in both treatment groups from Day 10 to Week 3. Thereafter, tacrolimus doses were, on average, 10% to 20% lower for ENVARSUS XR than in the tacrolimus capsule group. </paragraph>
                        <paragraph>Tacrolimus whole blood trough concentrations were monitored on Days 2, 3, 4, 7, 10, 14, 21, 30, 45, 60, 90, 120, 180,
270, and 360. On Day 2 predose, the proportion of patients in the ENVARSUS XR group with tacrolimus trough
concentration that were within, above and below the target tacrolimus trough concentration range of 6 to 11 ng/mL was
33%, 39%, and 28%, respectively, compared to 27%, 12%, and 61%, in the tacrolimus [immediate release] capsule group.
The average tacrolimus trough concentrations (per local laboratory reading) for the ENVARSUS XR group were above
the target range during the first week post-transplant, and higher than in the tacrolimus capsule group during the first 2
weeks post-transplant (see Figure 1). Thereafter, the mean tacrolimus trough concentrations were similar between the
treatment groups. </paragraph>
                        <br/>
                        <br/>
                        <paragraph ID="Figure2">
                           <content styleCode="bold">                                     Figure 1. Study 1 Tacrolimus Trough Concentrations by Treatment Group and Visits</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM62"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Concomitant Immunosuppressive Drugs</content>
                        </paragraph>
                        <paragraph>In Study 1, the concomitant use of mycophenolate products was comparable between the ENVARSUS XR and tacrolimus
[immediate-release] capsule treatment groups. Patients in both groups started MMF at an average dose of 1 gram twice
daily. The MMF daily dose was reduced to less than 2 grams over the course of the study; the mean MMF equivalent total
daily dose was approximately 1.5 grams at Month 12 in both treatment groups. Likewise, the average doses of
corticosteroids were comparable between the two treatment groups throughout the 12-month study period. Majority (96%
ENVARSUS XR and 99% tacrolimus [immediate-release] capsules) of the patients received two 20 mg doses of
basiliximab for antibody induction.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Efficacy Results</content>
                        </paragraph>
                        <paragraph>The efficacy failure rates including patients who developed biopsy-proven acute rejection (BPAR), graft failure, death,
and/or lost to follow-up at 12 months, as well as the rates of the individual events, are shown by treatment group in
<content styleCode="bold">Table 10</content> for the intent-to-treat population.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 10. Incidence of BPAR, Graft Loss, Death or Lost to Follow-up at 12 Months in De Novo Kidney Transplant Patients in Study 1</content>
                        </paragraph>
                        <table width="850" styleCode="Noautorules" ID="table10">
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> 95% CI was calculated using normal approximation.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"/>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR, MMF, steroids, and IL-2 receptor antagonist induction therapy 
                                                                                                                                                                <br/>N=268
                                                                                                                                                </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus
[Immediate-Release]
capsules, MMF,
steroids, and IL-2
receptor antagonist
induction therapy<br/>N=275
                                                                                                                                                </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Overall Treatment Difference of
efficacy failure compared to
tacrolimus immediate-release
(95% CI)<sup>a</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">-1.0%<br/>
                                                                                                                                                                (-7.6%, 5.6%)<br/>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Treatment Failure</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">50 (18.7%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">54 (19.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">           Biopsy Proven Acute Rejection      </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">36 (13.4%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">37 (13.5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">           Graft Failure</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">9 (3.4%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">11 (4.0%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">           Death                       </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8 (3.0%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">8 (2.9%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">           Lost to Follow-up</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4 (1.5%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">5 (1.8%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Glomerular Filtration Rates</content>
                        </paragraph>
                        <paragraph>Renal function was assessed as change from Day 30 (baseline) by eGFR calculated using the MDRD7 equation. Baseline
eGFR values were 53.8 ml/min/1.73 m<sup>2</sup> and 54.4 ml/min/1.73 m<sup>2</sup>, and 12 month eGFR values were 58.6 ml/min/1.73 m<sup>2</sup>
and 59.8 ml/min/1.73 m<sup>2</sup> in the ENVARSUS XR and the tacrolimus [immediate-release] capsule groups, respectively,
maintaining the small difference of approximately 1ml/min/1.73 m<sup>2</sup> between the treatment groups.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 2</content>
                        </paragraph>
                        <paragraph>Study 2 (NCT 00765661) was an open-label Phase 2 study conducted in de novo kidney transplant patients randomized to
once daily ENVARSUS XR (N=32) or twice daily tacrolimus [immediate-release] capsule(N=31). The study was
conducted in the US and patients received an organ from a deceased or living donor. Pharmacokinetics were evaluated
during the first 2 weeks with an additional 50-week treatment and follow-up to evaluate safety and efficacy.</paragraph>
                        <paragraph>Study 2 did not have any exclusion criteria based on cardiac disease or ECG findings but patients who received a kidney
from a non-heart-beating donor or with cold ischemia time ≥ 36 hours were excluded. Patients were randomized within 12
hours after transplantation and received the first dose of the study drug within 48 hours of graft reperfusion. Induction
treatment and concomitant immunosuppressive therapy were allowed per center-specific practices. </paragraph>
                        <paragraph>The mean age of study population was 47 years (range 23-69); 68% were male; 75% were Caucasian, 21% were African-
American, 5% were Asian. Two patients in each group withdrew early from the study due to adverse events.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tacrolimus Therapy</content>
                        </paragraph>
                        <paragraph>In Study 2, <content styleCode="italics">de novo</content> kidney transplant patients received a starting dosage of 0.14 mg/kg/day (given once daily) for ENVARSUS XR and 0.20 mg/kg/day (given twice daily) for tacrolimus [immediate-release] capsule. On Day 2 predose, the proportion of patients in the ENVARSUS XR group with tacrolimus trough concentration that were within, above, and
below 6 to 11 ng/mL was 53%, 11%, and 37%, respectively. In Study 1, the proportion of de novo kidney transplant
patients receiving a starting dose of 0.1 mg/kg/day of tacrolimus capsules that were within, above, and below 6 to 11
ng/mL on Day 2 predose was 27%, 12%, and 61%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Concomitant Immunosuppressive Drugs</content>
                        </paragraph>
                        <paragraph>In Study 2, concomitant therapy with mycophenolate products or azathioprine, corticosteroids, and antibody induction
was permitted but not required. The mean daily MMF, prednisone, and antibody induction doses were similar between the
ENVARSUS XR and tacrolimus capsules treatment groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Efficacy </content>
                        </paragraph>
                        <paragraph>There were no deaths or graft failures in Study 2. Acute rejection rates at 12 months were 3.1% (1/32) in the ENVARSUS
XR group and 6.5% (2/31) in the tacrolimus capsules group and 2 patients (one in each group) were lost to follow-up.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                     <component>
                        <observationMedia ID="MM62">
                           <text>chemical-structure</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="envarsusxr-figure-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="980453ad-b67b-489a-902d-9a136aa7524a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">14.2 Conversion Study from Tacrolimus Capsules in Stable Kidney Transplant Recipients</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 3</content>
                        </paragraph>
                        <paragraph>The conversion study, Study 3 (NCT00817206), was a Phase 3 randomized, open-label, multinational study evaluating once daily ENVARSUS XR when used to replace tacrolimus [immediate-release] capsules administered twice daily for maintenance immunosuppression to prevent acute allograft rejection in stable adult kidney transplant patients. Patients who received a kidney transplant 3 months to 5 years before study entry and on a stable dose of tacrolimus [immediate-release] capsules of at least 2 mg per day and tacrolimus whole blood trough concentrations between 4 and 15 ng/mL were randomized to 1) switch from twice daily tacrolimus capsules to once daily ENVARSUS XR (N=163) or 2) continue tacrolimus capsules twice daily (N=163). MMF or mycophenolate sodium (MPS), or azathioprine (AZA) and/or corticosteroids were allowed as concomitant immunosuppressants during the study period according to the standard of care at the participating site.</paragraph>
                        <paragraph>The mean age of study population was 50 years; 67% were male; 73% were Caucasian, 22% were African-American, 2% were Asian and 3% were categorized as other races. Living donors provided 35% of the organs and 65% of patients received a kidney transplant from a deceased donor. Premature discontinuation from treatment at the end of one year occurred in 13% of ENVARSUS XR patients and 6% of tacrolimus capsule patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Tacrolimus Therapy</content>
                        </paragraph>
                        <paragraph>In Study 3, stable kidney transplant patients converted to ENVARSUS XR at an average daily dose that was 80% of their tacrolimus [immediate-release] capsules daily dose prior to conversion. Mean tacrolimus whole blood trough concentrations were maintained within a relatively narrow range throughout the duration of the study for both the ENVARSUS XR conversion group and the tacrolimus capsules continuation group. At Week 1 (after 7 days of stable dosing), the mean ± SD tacrolimus trough concentrations were 7.2 ± 3.1 ng/mL for the ENVARSUS XR conversion group and 7.7 ± 2.5 for the tacrolimus capsules continuation group; the baseline values were 7.8 ± 2.3, and 8.0 ± 2.3, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="italics">MMF Therapy</content>
                        </paragraph>
                        <paragraph>In Study 3, the average daily mycophenolate equivalent doses were comparable between the ENVARSUS XR and
tacrolimus capsules treatment groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Efficacy Results</content>
                        </paragraph>
                        <paragraph>The efficacy failure rates including patients who developed BPAR, graft failure, death, and/or lost to follow-up at 12 months, as well as the rates of the individual events, are shown by treatment group in <content styleCode="bold">Table 11</content> for the modified intent-to-treat population.</paragraph>
                        <table width="750" styleCode="Noautorules" ID="table11">
                           <caption>Table 11. Incidence of BPAR, Graft Loss, Death or Lost to Follow-up at 12 Months in Stable Kidney Transplant
Patients in Study 3</caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> 95% CI was calculated using an exact method that is based on the standardized statistic and inverting a 2-sided test</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" styleCode="Lrule Toprule Rrule Botrule bold"/>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">ENVARSUS XR ± Steroids ± MMF, MPS, or AZA 
										<br/>N=162
									</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule bold">Tacrolimus
[Immediate-Release]
Capsules ± Steroids ±
MMF, MPS, or AZA
										<br/>N=162
									</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule"> Treatment Failure</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4 (2.5%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">4 (2.5%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">Overall Treatment Difference of efficacy failure compared to tacrolimus immediate-release<br/>
										(95% CI)<sup>a</sup>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">0%<br/>
										(-4.2%, 4.2%)
									</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">              Biopsy Proven Acute Rejection	</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2 (1.2%)	</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2 (1.2%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">              Graft Failure</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">0%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">0%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">              Death		</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">2 (1.2%)</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1 (0.6%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule">              Lost to Follow-up</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">0%</td>
                                 <td align="center" styleCode="Lrule Toprule Rrule Botrule">1 (0.6%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Glomerular Filtration Rates</content>
                        </paragraph>
                        <paragraph>The mean estimated glomerular filtration rates (eGFR), using the Modification of Diet in Renal Disease 7 (MDRD7) formula, were 61.5 ml/min/1.73 m<sup>2</sup> and 60.0 ml/min/1.73 m<sup>2</sup> at baseline (Day 0) and 62.0 ml/min/1.73 m<sup>2</sup> and 61.4 ml/min/1.73 m<sup>2</sup> at 12 months in the ENVARSUS XR and tacrolimus capsules treatment groups, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="021d8d0e-ee9b-473d-981a-6c467afc60f1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title mediaType="text/x-hl7-title+xml">16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ENVARSUS XR is supplied in round HDPE bottles with twist-off caps (see <content styleCode="bold">Table 12</content>); the statement ‘ONCE-DAILY’ appears on its labels.</paragraph>
                  <table width="750" styleCode="Noautorules" ID="table12">
                     <caption>Table 12. Strengths of ENVARSUS XR</caption>
                     <col width="10%"/>
                     <col width="50%"/>
                     <col width="30%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule">Strength</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">Description</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">NDC</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule">0.75 mg</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">Oval, white to off-white uncoated extended-release tablet, debossed with “0.75” on one side and “TCS” on the other side.</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">30-count (NDC 68992-3075-3) <br/>100-count (NDC 68992-3075-1)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule">1 mg</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">Oval, white to off-white uncoated extended-release
tablet, debossed with “1” on one side and “TCS” on the
other side.</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">30-count (NDC 68992-3010-3)<br/>100-count (NDC 68992-3010-1)</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule">4 mg</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">Oval, white to off-white uncoated extended-release
tablet, debossed with “4” on one side and “TCS” on the
other side.</td>
                           <td styleCode="Lrule Toprule Rrule Botrule">30-count (NDC 68992-3040-3)<br/>100-count (NDC 68992-3040-1)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Store and Dispense</content>
                     <br/>Store at 25 °C (77 °F); excursions permitted to 15 °C to 30 °C (59 °F to 86 °F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20240416"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="c8323363-6c78-4f56-9de3-b53dae59f59a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title mediaType="text/x-hl7-title+xml">17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20240416"/>
               <component>
                  <section ID="S17.1">
                     <id root="72b7da08-4af4-4aa0-9906-31da1141483f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.1 Administration</title>
                     <text>
                        <paragraph>Advise patients to:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Inspect their ENVARSUS XR medicine when they receive a new prescription and before taking it. If the appearance
of the tablet is not the same as usual, or if dosage instructions have changed, advise patients to contact their
healthcare provider as soon as possible to make sure that you have the right medicine. Other tacrolimus products
cannot be substituted for ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S5.3"> Warnings and Precautions (5.3)</linkHtml>]</content>.</item>
                           <item>Take once-daily ENVARSUS XR at the same time every day (preferably in the morning) on an empty stomach. at
least 1 hour before or at least 2 hours after a meal to ensure consistent and maximum possible drug concentrations in
the blood.</item>
                           <item>Swallow tablet whole with liquid, preferably water. Do not chew, divide or crush tablet.</item>
                           <item>Avoid alcoholic beverages, grapefruit, and grapefruit juice while on ENVARSUS XR <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml> and <linkHtml href="#S7.2"> Drug Interactions (7.2)</linkHtml>]</content>.</item>
                           <item>Take a missed dose as soon as possible but not more than 15 hours after the scheduled time (i.e., for a missed 8 AM
dose, take it no later than 10 PM). Beyond the 15-hour timeframe, instruct the patient to wait until the usual
scheduled time the following morning to take the next regularly scheduled dose. Do not take two doses at the same
time <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.2">
                     <id root="2506ea4e-ba0b-4060-950f-a81660182ec5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.2 Development of Lymphoma and Other Malignancies</title>
                     <text>
                        <paragraph>Inform patients that they are at an increased risk of developing lymphomas and other malignancies, particularly of the skin, due to immunosuppression. Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and use a sunscreen with a high protection factor <content styleCode="italics">[see <linkHtml href="#SBW">Boxed Warning</linkHtml> and <linkHtml href="#S5.1"> Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.3">
                     <id root="085f6f1d-fd27-44a6-b0db-70b02af385e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.3 Increased Risk of Infection</title>
                     <text>
                        <paragraph>Inform patients that they are at an increased risk of developing a variety of infections, including opportunistic infections,
due to immunosuppression and to contact their physician if they develop any symptoms of infection such as fever, sweats
or chills, cough or flu-like symptoms, muscle aches, or warm, red, painful areas on the skin <content styleCode="italics">[see <linkHtml href="#SBW">Boxed Warning</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.4">
                     <id root="58e26cde-6244-4480-92bb-fafba7aa237f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.4 New Onset Diabetes After Transplant</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can cause diabetes mellitus and should be advised to contact their physician if they
develop frequent urination, increased thirst or hunger <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.5">
                     <id root="94fa0dcc-252a-4e23-ba92-e5bbd4eea53a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.5 Nephrotoxicity</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can have toxic effects on the kidney that should be monitored. Advise patients to
attend all visits and complete all blood tests ordered by their medical team <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.6">
                     <id root="8cb22e9b-a76b-45e4-aefe-a7d4580cdc75"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.6 Neurotoxicity</title>
                     <text>
                        <paragraph>Inform patients that they are at risk of developing adverse neurologic effects including seizure, altered mental status, and
tremor. Advise patients to contact their physician should they develop vision changes, delirium, or tremors <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.7">
                     <id root="2b386103-fbf6-42d4-a56a-44fea88fe8a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.7 Hyperkalemia</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can cause hyperkalemia. Monitoring of potassium levels may be necessary,
especially with concomitant use of other drugs known to cause hyperkalemia <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.8">
                     <id root="b0d98068-6925-4246-9fcb-c503d115ce8d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.8 Hypertension</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can cause high blood pressure which may require treatment with anti-hypertensive
therapy. Advise patients to monitor their blood pressure <content styleCode="italics">[see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.9">
                     <id root="b5a70027-32c4-4b3b-99e1-5b6d92f76a4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.9 Thrombotic Microangiopathy</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can cause blood clotting problems. The risk of this occurring increases when patients take ENVARSUS XR and sirolimus or everolimus concomitantly, or when patients develop certain infections. Advise them to seek medical attention promptly if they develop fever, petequiae or bruises, fatigue, confusion, jaundice, oliguria <content styleCode="italics">[see <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.10">
                     <id root="2e3d3c9b-3648-4a17-ac9a-876d9fc29dc3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.10 Drug Interactions</title>
                     <text>
                        <paragraph>Instruct patients to tell their healthcare providers when they start or stop taking any concomitant medications, including
prescription and non-prescription medicines, natural or herbal remedies, dietary supplements and vitamins. Some
medications could alter tacrolimus concentrations in the blood and thus may require the adjustment of the dosage of
ENVARSUS XR. Advise patients to avoid grapefruit, grapefruit juice and alcoholic beverages <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9</linkHtml>, <linkHtml href="#S5.13">5.13)</linkHtml> and <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.11">
                     <id root="3ffa32be-429a-44f0-8d99-9cffbe184f6f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.11 Pregnancy, Lactation and Infertility</title>
                     <text>
                        <paragraph>Inform women of childbearing potential that ENVARSUS XR can harm the fetus. Instruct male and female patients to
discuss with their healthcare provider family planning options including appropriate contraception. Also discuss with
pregnant patients the risks and benefits of breastfeeding their infant <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.2">8.2</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph> Encourage female transplant patients who become pregnant and male patients who have fathered a pregnancy, exposed to
immunosuppressants including tacrolimus, to enroll in the voluntary Transplantation Pregnancy Registry International. To
enroll or register, patients can call the toll-free number 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</paragraph>
                        <paragraph>Based on animal studies, ENVARSUS XR may affect fertility in males and females <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
               <component>
                  <section ID="S17.12">
                     <id root="0afd7219-a30e-43e5-9f1b-708a5d4180b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title mediaType="text/x-hl7-title+xml">17.12 Immunizations</title>
                     <text>
                        <paragraph>Inform patients that ENVARSUS XR can interfere with the usual response to immunizations and that they should avoid
live vaccines <content styleCode="italics">[see <linkHtml href="#S5.11">Warnings and Precautions (5.11)</linkHtml>]</content>.</paragraph>
                        <paragraph>Product of Germany</paragraph>
                        <paragraph>Manufactured by:<br/>
							Rottendorf Pharma GmbH<br/>
							59320 Ennigerloh<br/>
							North Rhine-Westphalia<br/>
							Germany
						</paragraph>
                        <paragraph>Manufactured for: <br/>
							Veloxis Pharmaceuticals, Inc.<br/>
							Cary, North Carolina 27518<br/>
							United States
						</paragraph>
                     </text>
                     <effectiveTime value="20240416"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="SMGD">
               <id root="afa65379-94f3-4260-8fb0-c8be0fe1fa0b"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table ID="MG" width="100%">
                     <colgroup>
                        <col width="2%" align="left" valign="top"/>
                        <col width="28%" align="left" valign="top"/>
                        <col width="30%" align="left" valign="top"/>
                        <col width="40%" align="left" valign="top"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td colspan="3" align="left">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                           <td colspan="2" align="right">Revised: 4/2024</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>
                              <content styleCode="bold">ENVARSUS XR® </content>(En var' sus XR)<br/>
                              <content styleCode="bold">(tacrolimus extended-release tablets)</content>
                              <br/>
                              for oral use
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Read this Medication Guide before you start taking ENVARSUS XR and each time you get a refill.
There may be new information. This information does not take the place of talking with your healthcare
provider about your medical condition or your treatment. If you have any questions about ENVARSUS
XR, ask your healthcare provider or pharmacist.</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about ENVARSUS XR?<br/> ENVARSUS XR can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="ordered" styleCode="Arabic">
                                 <item>
                                    <content styleCode="bold">Increased risk of cancer.</content> People who take ENVARSUS XR have an increased risk of getting some kinds of cancer, including skin and lymph gland cancer (lymphoma).</item>
                                 <item>
                                    <content styleCode="bold">Increased risk of infection.</content> ENVARSUS XR is a medicine that affects your immune system. ENVARSUS XR can lower the ability of your immune system to fight infections. Serious infections can happen in people receiving ENVARSUS XR that can cause death.<br/>
                                    <content styleCode="bold">Call your healthcare provider right away if you have symptoms of an infection such as:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule"/>
                           <td styleCode="Botrule" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>fever</item>
                                 <item>sweats or chills</item>
                              </list>
                           </td>
                           <td styleCode="Botrule" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>cough or flu-like symptoms</item>
                                 <item>muscle aches</item>
                              </list>
                           </td>
                           <td styleCode="Botrule Rrule" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>warm, red, or painful areas on your skin</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is ENVARSUS XR?</content>
                              </paragraph>
                              <list>
                                 <item>ENVARSUS XR is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant.</item>
                                 <item>ENVARSUS XR is an extended-release tablet and is not the same as tacrolimus extended-release
capsules, tacrolimus immediate-release capsules or tacrolimus for oral suspension. Your healthcare
provider should decide what medicine is right for you.</item>
                              </list>
                              <paragraph> It is not known if Envarsus XR is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Who should not take ENVARSUS XR?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not take ENVARSUS XR if you:</content>
                              </paragraph>
                              <list>
                                 <item>are allergic to tacrolimus or any of the ingredients in ENVARSUS XR. See the end of this Medication Guide for a complete <linkHtml href="#INGREDIENT01">list of ingredients</linkHtml> in ENVARSUS XR.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I tell my doctor before taking ENVARSUS XR?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before you take ENVARSUS XR, tell your healthcare provider about all your medication conditions, including if you:</content>
                              </paragraph>
                              <list>
                                 <item>plan to receive any live vaccines. Ask your healthcare provider if you are not sure if your vaccine
is a live vaccine.</item>
                                 <item>have or have had liver, kidney or heart problems.</item>
                                 <item>are pregnant or plan to become pregnant. ENVARSUS XR may harm your unborn baby. 
					 <list listType="unordered" styleCode="circle">
                                       <item>If you are able to become pregnant, you should use effective birth control before and during
treatment with ENVARSUS XR. Talk to your healthcare provider about birth control methods
that may be right for you.</item>
                                       <item>Males who have female partners that are able to become pregnant should also use effective
birth control before and during treatment with ENVARSUS XR. Talk to your healthcare
provider before starting treatment with ENVARSUS XR about birth control methods that may
be right for you.</item>
                                       <item>There is a pregnancy registry for females who become pregnant and males who have fathered
a pregnancy during treatment with ENVARSUS XR. The purpose of this registry is to collect
information about your health and of your baby. To enroll in this voluntary registry, call 1-877-
955-6877 or register at <linkHtml href="https://www.transplantpregnancyregistry.org">https://www.transplantpregnancyregistry.org</linkHtml>.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. ENVARSUS XR passes into your breast milk. You and
your healthcare provider should decide if you will breastfeed while taking ENVARSUS XR</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold"> Tell your healthcare provider about all the medicines you take,</content> including prescription and
over-the-counter medicines, vitamins, natural, herbal or nutritional supplements.</paragraph>
                              <paragraph>ENVARSUS XR may affect the way other medicines work, and other medicines may affect
how ENVARSUS XR works.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you take:</content>
                              </paragraph>
                              <list>
                                 <item>sirolimus (RAPAMUNE):</item>
                                 <item>everolimus</item>
                                 <item>cyclosporine (GENGRAF, NEORAL, and SANDIMMUNE)</item>
                                 <item>medicines called aminoglycosides that are used to treat bacterial infections</item>
                                 <item>ganciclovir (CYTOVENE IV, VALCYTE)</item>
                                 <item>amphotericin B (ABELCET, AMBISOME)</item>
                                 <item>cisplatin</item>
                                 <item>antiviral medicines called nucleoside reverse transcriptase inhibitors</item>
                                 <item>antiviral medicines called protease inhibitors</item>
                                 <item>water pill (diuretic)</item>
                                 <item>medicine to treat high blood pressure</item>
                                 <item>erythromycin</item>
                                 <item>danazol</item>
                                 <item>ethyinyl estradiol</item>
                                 <item>cimetidine</item>
                                 <item>lansoprazole</item>
                                 <item>omeprazole</item>
                                 <item>azole antifungals</item>
                                 <item>imatinib</item>
                                 <item>nilotinib</item>
                                 <item>nelfinavir (VIRACEPT)</item>
                                 <item>telaprevir (INCIVEK)</item>
                                 <item>boceprevir)</item>
                                 <item>ritonavir (PAXLOVID, KALETRA, NORVIR, TECHNIVIE, VIEKIRA PAK, VIEKIRA XR)</item>
                                 <item>letermovir (PREVYMIS)</item>
                                 <item>ketoconazole</item>
                                 <item>itraconazole (ONMEL, SPORANOX)</item>
                                 <item>voriconazole (VFEND)</item>
                                 <item>posaconazole</item>
                                 <item>caspofungin (CANCIDAS)</item>
                                 <item>clarithromycin (BIAXIN, BIAXIN XL, PREVPAC)</item>
                                 <item>troleandomycin</item>
                                 <item>chloramphenicol</item>
                                 <item>nefazodone</item>
                                 <item>Schisandra sphenanthera extracts</item>
                                 <item>cobicistat</item>
                                 <item>rifampin (RIFADIN, RIFAMATE, RIFATER, RIMACTANE)</item>
                                 <item>rifabutin (MYCOBUTIN)</item>
                                 <item>medicine to treat seizures (phenytoin, carbamazepine, phenobarbital</item>
                                 <item>St. John’s Wort</item>
                                 <item>amiodarone (NEXTERONE, PACERONE)</item>
                                 <item>cannabidiol (EPIDIOLEX)</item>
                                 <item>magnesium and aluminum hydroxide antacids</item>
                                 <item>metoclopramide</item>
                                 <item>methylprednisolone</item>
                                 <item>prednisone </item>
                              </list>
                              <paragraph>Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. ENVARSUS XR may affect the way other medicines work, and other medicines may affect how ENVARSUS XR works.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take ENVARSUS XR?</content>
                              </paragraph>
                              <list>
                                 <item>Take ENVARSUS XR exactly as your healthcare provider tells you to take it.</item>
                                 <item>Your healthcare provider may change your dose of ENVARSUS XR if needed. <content styleCode="bold">Do not</content> stop taking or
change your dose of ENVARSUS XR without talking to your healthcare provider.</item>
                                 <item>Take ENVARSUS XR 1-time daily with fluid (preferably water) on an empty stomach, at least 1 hour
before or at least 2 hours after a meal, at the same time each day (preferably in the morning). Taking ENVARSUS XR at the same time each day helps to keep the amount of ENVARSUS XR in your body at a steady level.</item>
                                 <item>Take ENVARSUS XR tablets whole. <content styleCode="bold">Do not</content> chew, divide, crush, or dissolve ENVARSUS XR tablets
before swallowing. If you cannot swallow ENVARSUS XR tablets whole, tell your healthcare provider.</item>
                                 <item>If you miss your dose of ENVARSUS XR, it should be taken as soon as possible, but no longer than 15
hours after missing your dose. If the time after missing your dose is more than 15 hours, the missed dose
should be skipped and the next dose should be taken the following morning at your regularly scheduled
time. <content styleCode="bold">Do not</content> take 2 doses at the same time.</item>
                                 <item>If you take too much ENVARSUS XR, call your healthcare provider or go to the nearest hospital
emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while taking ENVARSUS XR?</content>
                              </paragraph>
                              <list>
                                 <item>Live vaccines such as the flu vaccine through your nose, measles, mumps, rubella, polio by mouth, BCG (TB vaccine), yellow fever, chicken pox (varicella), or typhoid.</item>
                                 <item>Exposure to sunlight and UV light such as tanning machines. Wear protective clothing and use a sunscreen.</item>
                                 <item>You should not eat grapefruit or drink grapefruit juice while taking ENVARSUS XR.</item>
                                 <item>You should not drink alcohol while taking ENVARSUS XR.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of ENVARSUS XR?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">ENVARSUS XR may cause serious side effects, including:</content>
                              </paragraph>
                              <list>
                                 <item>
                                    <content styleCode="bold">See “What the most important information I should know about ENVARSUS XR?”</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">problems from medication errors such as graft rejection and other serious reactions.</content> People who take ENVARSUS XR have sometimes been given the wrong medicine because some medicines have the same ingredient (tacrolimus) as ENVARSUS XR. <content styleCode="bold">Check your ENVARSUS XR when you get a new prescription to make sure you have received the right medicine.</content>
                                    <list>
                                       <item>Call your healthcare provider right away if you think you were given the wrong medicine.</item>
                                       <item>Ask your healthcare provider or pharmacist if you are not sure what ENVARSUS XR should look like.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">high blood sugar (diabetes)</content>. High blood sugar is a serious, but common side effect of ENVARSUS XR. Your healthcare provider may do certain tests to check for diabetes while
you take ENVARSUS XR. Call your healthcare provider right away if you have:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>frequent urination</item>
                                 <item>confusion</item>
                                 <item>fruity smell on your breath</item>
                              </list>
                           </td>
                           <td align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>increased thirst or hunger</item>
                                 <item>drowsiness</item>
                                 <item>nausea, vomiting, or stomach pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>blurred vision</item>
                                 <item>loss of appetite</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list>
                                 <item>
                                    <content styleCode="bold">kidney problems</content>. Kidney problems are serious, but common side effects of ENVARSUS XR. Your healthcare provider may do certain tests to check for kidney function while you take ENVARSUS XR.</item>
                                 <item>
                                    <content styleCode="bold">nervous system problems</content>. Nervous system problems are a serious, but common side effect of ENVARSUS XR. Call your healthcare provider right away if you get any of these symptoms while taking ENVARSUS XR:</item>
                                 <item>
                                    <content styleCode="bold">high levels of potassium in your blood</content>. High levels of potassium in your blood are a serious, but common side effect of ENVARSUS XR. Your healthcare provider may do certain tests to check your potassium level while you take ENVARSUS XR.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>confusion</item>
                                 <item>numbness and tingling</item>
                                 <item>vision changes</item>
                              </list>
                           </td>
                           <td align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>coma</item>
                                 <item>headache</item>
                                 <item>muscle tremors</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="circle">
                                 <item>seizures</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <list>
                                 <item>
                                    <content styleCode="bold">high blood pressure</content>. High blood pressure is a serious, but common side effect of ENVARSUS XR. Your healthcare provider will monitor your blood pressure while you take ENVARSUS XR.</item>
                                 <item>
                                    <content styleCode="bold">changes in the electrical activity of your heart (QT prolongation).</content>   Your healthcare provider may do certain tests to check your heart function while you take ENVARSUS XR.
                                 </item>
                                 <item>
                                    <content styleCode="bold">severe low blood cell count (anemia)</content>. Your healthcare provider may stop your treatment with ENVARSUS XR if you develop a severe low blood cell count.
                                 </item>
                                 <item>
                                    <content styleCode="bold">blood clotting problems: </content> Tell your healthcare provider right away if you have fever and bruising under the skin that may appear as red dots, with or without unexplained tiredness, confusion, yellowing of the skin or eyes, decreased urination. When taken with sirolimus or everolimus, or when you develop certain infections, the risk of developing these symptoms may increase.
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of ENVARSUS XR in people who received a kidney transplant are:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Lrule" align="left">
                              <list listType="unordered" styleCode="disc">
                                 <item>diarrhea</item>
                                 <item>low red blood cell count (anemia)</item>
                              </list>
                           </td>
                           <td align="left">
                              <list listType="unordered" styleCode="disc">
                                 <item>urinary tract     infection</item>
                                 <item>constipation</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="disc">
                                 <item>swelling in the arms, hands, or legs (peripheral edema)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of ENVARSUS XR in people who are switching from immediate-release tacrolimus to ENVARSUS XR are </content> diarrhea and high blood creatinine.</paragraph>
                              <paragraph>These are not all the possible side effects of ENVARSUS XR. For more information, ask your healthcare
provider or pharmacist.<br/>
                                 <br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store ENVARSUS XR?</content>
                              </paragraph>
                              <list>
                                 <item>Store ENVARSUS XR at room temperature between 68 ºF to 77 ºF (20 °C to 25 ºC).</item>
                                 <item>Safely throw away medicine that is out of date or no longer needed.</item>
                              </list>
                              <paragraph styleCode="bold">Keep ENVARSUS XR and all medicines out of reach of children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of ENVARSUS XR.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ENVARSUS XR for a condition for which it was not prescribed. Do not give ENVARSUS XR to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <br/>
                              <paragraph>This Medication Guide summarizes the most important information about ENVARSUS XR. If you would like
more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for
information about ENVARSUS XR that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in ENVARSUS XR?</content>
                              </paragraph>
                              <paragraph ID="INGREDIENT01">
                                 <content styleCode="bold">Active ingredient:</content> tacrolimus USP.<br/>
                                 <content styleCode="bold">Inactive ingredients:</content> hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF.</paragraph>
                              <br/>
                              <paragraph>Manufactured by: <content styleCode="bold">Rottendorf Pharma GmbH,</content> 59320 Ennigerloh, North Rhine-Westphalia, Germany  <br/>
                     Manufactured for: <content styleCode="bold">Veloxis Pharmaceuticals, Inc.,</content> Cary, North Carolina 27518, United States <br/>
				For more information, go to www.ENVARSUSXR.com or call 1-844-Veloxis (1-844-835-6947).
				</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240416"/>
            </section>
         </component>
         <component>
            <section ID="SPDP">
               <id root="91983ea6-303b-4ad2-937b-a80282c569b4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - Envarsus 0.75 mg 30 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3075-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.75 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert<br/> for dosage information.</paragraph>
                  <paragraph>Always dispense with a<br/> Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 0.75 mg 30 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3075-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.75 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 0.75 mg 100 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3075-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.75 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert <br/>for dosage information.</paragraph>
                  <paragraph>Always dispense with a <br/>Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 0.75 mg 100 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3075-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">0.75 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM4"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 1 mg 30 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3010-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert <br/>for dosage information.</paragraph>
                  <paragraph>Always dispense with a<br/> Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 1 mg 30 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3010-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM6"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 1 mg 100 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3010-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert<br/> for dosage information.</paragraph>
                  <paragraph>Always dispense with a<br/> Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM7"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 1 mg 100 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3010-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM8"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 4 mg 30 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3040-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert<br/> for dosage information.</paragraph>
                  <paragraph>Always dispense with a<br/> Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM9"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 4 mg 30 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3040-3</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Tablets </content>         Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM10"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 4 mg 100 Count Carton Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3040-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide,<br/> or crush tablet.</content>
                  </paragraph>
                  <paragraph>Dosage: See Package Insert<br/> for dosage information.</paragraph>
                  <paragraph>Always dispense with a <br/>Medication Guide</paragraph>
                  <paragraph>For oral use only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM11"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                        <br/>PRINCIPAL DISPLAY PANEL - Envarsus 4 mg 100 Count Bottle Label<br/>
                        <br/>
                     </content>
                  </paragraph>
                  <paragraph>NDC 68992-3040-1</paragraph>
                  <paragraph>
                     <content styleCode="bold">Envarsus XR<sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(tacrolimus <br/>extended-release tablets)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">ONCE-DAILY</content>
                  </paragraph>
                  <paragraph>Always Dispense With a Medication Guide</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablet whole.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not chew, divide, or crush tablet.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold underline">100 Tablets </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Veloxis PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM12"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240416"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Envarsus 0.75mg 30 count Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-0pt75mg-carton-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Envarsus 0.75mg 30 count bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-0pt75mg-bottle-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Envarsus 0.75mg 100 count Carton Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-0pt75mg-carton-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Envarsus 0.75mg 100 count bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-0pt75mg-bottle-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Envarsus 1mg 30 count carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-1mg-carton-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Envarsus 1mg 30 count bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-1mg-bottle-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Envarsus 1mg 100 count carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-1mg-carton-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Envarsus 1mg 100 count bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-1mg-bottle-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Envarsus 4mg 30 count Carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-4mg-carton-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Envarsus 4mg 30 count bottle label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-4mg-bottle-30-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM11">
                     <text>Envarsus 4mg 100 count Carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-4mg-carton-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM12">
                     <text>Envarsus 4mg 100 count bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="envarsusxr-4mg-bottle-100-count.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>